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ABSTRACT 
Active efflux of antimicrobial agents is one of the most important strategies that 
bacteria use to ensure their survival in a toxic extracellular environment.  Our interest is to 
elucidate the structural and functional relationships of bacterial multidrug efflux transporters 
that give rise to antibiotic resistance.  In this dissertation, I focus on studying two specific 
groups, the multidrug and toxic compound extrusion (MATE) family and the resistance-
nodulation-division (RND) family, of multidrug efflux transporters.  The functions of the two 
MATE efflux pumps, NorM of Neisseria gonorrhoeae and YdhE of Escherichia coli, are 
characterized using a variety of biochemical assays, including drug susceptibility and 
transport assays.  Direct measurements of efflux allow us to confirm that NorM behaves as a 
Na
+
-dependent transporter.  The capacity of NorM and YdhE to recognize structurally 
divergent compounds is also examined using steady-state fluorescence polarization assays.  
The results suggest that NorM and YdhE bind these antimicrobials with dissociation 
constants (KDs) in the micromolar range.  
In addition, I present the crystal structures of the CusA transporter, the only heavy-
metal efflux (HME) pump of the RND family in E. coli, in the absence and presence of Cu(I) 
and Ag(I) ions.  These are the first structures of any efflux pumps belonging to the HME-
RND family.  Surprisingly, the binding of Cu(I) and Ag(I) triggers significant conformational 
changes in both the periplasmic and transmembrane domains of the pump.  Based on the 
crystal structures and biochemical studies, I put forward my hypothesis that CusA is capable 
of actively picking up metal ions from the cytoplasm as well as the periplasmic space, 
utilizing the methionine pairs/clusters in the pump to bind and export metal ions.  A stepwise 
shuttle mechanism is probably employed by the pump to extrude these heavy metals.  
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CHAPTER 1.  General Introduction 
Bacterial multidrug resistance 
Since the discovery of penicillin in 1928, antibiotics have had been used to cure many 
potentially lethal bacterial infections.  As a consequence of the widespread use of these 
antibiotics, an increasing number of pathogens are becoming resistance to multiple 
antibiotics.  One of the most serious threats to human health was posed with the emergence 
of vancomycin resistance in methicilllin-resistant Staphylococcus aureus (MRSA) (1).  To 
date it has been found to be more difficult to treat bacterial infections with standard therapies.  
Bacteria can work against the action of antibiotics through various strategies (2).  These 
include altering or modifying the target, enzymatic inactivating the drug, preventing an 
antibiotic from entering the bacterial cell, and actively transporting an antibiotic out of the 
cell.  Except for the intrinsic resistance to given antibacterial drugs, bacteria can resist 
antibiotics in a broad range by acquiring resistance genes from other species (3). 
Bacterial multidrug efflux transporters are currently categorized in five different 
families: the major facilitator (MF) superfamily (4-6), the resistance nodulation cell division 
(RND) family (7), the small multidrug resistance (SMR) family (8), the ATP binding cassette 
(ABC) family (9) and the multidrug and toxic compound extrusion (MATE) family (10).  
The ABC family transporters take the free energy generated from ATP hydrolysis to expel 
toxic substances out of cells.  Efflux transporters in the other families, however, utilize the 
transmembrane electrochemical gradient of protons or sodium ions to extrude these harmful 
substrates from cells.  In this dissertation, I mainly focus on the study of representative 
transporters belonging to the RND and MATE families. 
2 
 
Multidrug transporters have been identified in both mammalian and bacterial cells.  
An understanding of how these efflux transporters works would allow us to find better 
approaches for treating bacterial infections and cancer.  The key to understand how these 
efflux pumps operate involves the determination of the structures of representative 
transporters and the elucidation of the conformational changes that accompany with drug 
translocation across the cell membrane.  
 
Multidrug efflux pumps of the MATE family 
The MATE family is the most recently classified family with only about twenty 
transporters having been identified so far.  MATE transporters are typically composed of 12 
putative transmembrane domains, and have been found in all major kingdoms (Eukarya, 
Archaea, and Eubacteria).  NorM of Vibrio parahaemolyticus, the first characterized MATE 
transporter, is a Na
+
 /drug antiporter that confers resistance to dyes, fluoroquinolones and 
aminoglycosides (11).  Subsequently, other MATE efflux pumps have been identified in 
many pathogenic bacteria, including Acinetobacter baumannii (12), Brucella melitensis (13), 
Clostridium difficile (14), Haemophilus influenza (15), Neisseria gonorrhoeae (16), 
Neisseria meningitides (16), Pseudomonas aeruginosa (17), Staphylococcus aureus (18), and 
Vibrio cholera (19-21).  The main substrates for these MATE transporters are cationic and 
aromatic compounds.  Until now, little knowledge has been obtained regarding the structures 
and fundamental mechanisms that give rise to multidrug resistance mediated by this novel 
MATE family of transporters.  Nonetheless, the presence of these multidrug efflux pumps in 
pathogens highlights the potential clinical significance of this transporter family.  In this 
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dissertation, I target the NorM pump of N. gonorrhoeae and the YdhE transporter of 
Escherichia coli, and characterize the functions of these two MATE-type proteins.  
N. gonorrhoeae, a gram-negative diplococcus, is found only in humans and causes 
one of the most common sexually transmitted diseases.  This pathogen is progressively 
shown to be resistant to multiple antibiotics, including penicillin, tetracycline, erythromycin, 
and ciprofloxacin.  In April 2007, the Centers for Diseases Control and Prevention (CDC) 
officially added gonorrhea to the list of antibiotic resistant „super bugs‟ (22).  In the USA, it 
is estimated that 700,000-800,000 new cases occur each year, with a cost of about $1.1 
billion annually for this infection (23).  While we are aware of the growing public health 
concern resulted from the antimicrobial resistance developed in N. gonorrhoeae, four 
multidrug transporters have been identified in N. gonorrhoeae.  These transporters are MtrD 
(RND) (24-26), FarB (MF) (27), MacB (ABC) (28) and NorM (MATE).  The gonococcal 
NorM appears to recognize and export a number of cationic toxic compounds, including 
ethidium bromide, acriflavin, 2-N-methylellipticinium, and ciprofloxacin (16). 
The E. coli YdhE multidrug transporter is homologous to N. gonorrhoeae NorM (11, 
29, 30).  These two MATE transporters share 34% identity and 70% similarity.  Both YdhE 
and NorM are membrane proteins, consisting of 457 and 459 amino acid residues, 
respectively.  Our goal is to understand the structural and functional relationship of these 
MATE transporters using x-ray crystallography and different biochemical methods.  
Particularly, I investigate the active molecular functions of N. gonorrhoeae NorM and E. coli 
YdhE by conducting heterogenous drug susceptibility test, in vivo transport assay, and a 
novel fluorescence polarization assay.  The information has allowed us to understand the 
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fundamental rules that govern drug recognition and extrusion in the MATE family of 
multidrug efflux pumps. 
 
Multidrug efflux pumps of the RND family 
The RND-type transporters play a major role in mediating clinically relevant 
antibiotic resistance in Gram-negative bacteria.  These transporters can work against a broad 
range of structural unrelated toxic compounds.  For example, E. coli AcrB is capable of 
extruding a variety of antibiotics, detergents, dyes and simple organic solvents (31).  A 
typical RND efflux system consists of three fundamental components: an inner membrane 
RND transporter, a periplasmic membrane fusion protein (MFP) and an outer membrane 
protein (OMP) channel.  The resulting tripartite complex spans both the inner and outer 
membranes and exports these toxic substrates directly out of the bacterial cell (32, 33).  The 
energy source of the process comes from proton import, which is utilized by the inner 
membrane RND transporter.  
The RND family can be further divided into two sub-families, the hydrophobic and 
amphiphilic efflux RND (HAE-RND) and heavy-metal efflux RND (HME-RND) sub-
families.  As a Gram-negative bacterium, E. coli possesses seven RND transporters.  Six of 
these efflux pumps, AcrB (31, 34-41), AcrD (42), AcrF (43), MdtB (44, 45), MdtC (44, 45) 
and YhiV (46, 47), are categorized as the HAE-RND sub-family.  These six transporters are 
responsible for the intrinsic tolerance of antibiotics and toxic organic compounds.  The rest 
of the transporter CusA belongs to the HME-RND family and is found to be capable of 
exporting copper (I) and silver (I) ions out of E. coli cell (48, 49).  
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Among all known RND transporters, the X-ray structures of E. coli AcrB (35, 36, 38, 
39) and Pseudomonas aeruginosa MexA (50) have been determined.  Based on the crystal 
structures, the functional unit of these efflux pumps is a homotrimer.  In each monomer of 
the AcrB pump, there are 12 transmembrane (TM) helices spanning the entire cytoplasmic 
membrane, and two large periplasmic loops protruding approximately 80Å into the periplasm.  
A large cavity with a diameter of approximate 35Å is formed in the transmembrane region 
within the trimer.  The large periplasmic domain of the pump mainly comprises two distinct 
loops located between TM1 and 2, and TM7 and 8 (51).  It has been well characterized that 
the AcrB transporter interacts with TolC (OMP) and AcrA (MFP) to form a functional 
tripartite RND efflux complex (52).  The crystal structures of these three individual 
components are all available (53-55).  A proposed assembled model of the tripartite RND 
efflux complex, based on cross-linking and computation method, has suggested that this 
efflux system is in the form of AcrB3-AcrA3-TolC3 (56).  A pathway for transporting 
substrates in the pump has been shown through a tunnel formed by the periplasmic domain 
using computational calculation (40, 50).  However, the fundamental mechanisms involved 
in the assembly and drug transport of this tripartite system are still not clear and confirmative.  
Towards our goal to elucidate the structures and fundamental mechanisms that give 
rise to the recognition and extrusion of toxic compounds in RND efflux transporters, we 
focus on studying the E. coli CusCBA HME-RND efflux system.  This study has provided us 
with the understanding of heavy-metal tolerance in bacteria.  
As an alternative clinical treatment of bacterial infections, both silver and copper 
exhibit antimicrobial activities against a broad range of microorganisms at low 
concentrations.  Although copper is required by most microorganisms in trace amount to 
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maintain their lives, excess amount of copper is extremely toxic (57).  It has been reported 
that silver and copper compounds effectively eliminate Legionella in drinking water 
pipelines (58).  Silver compounds are comparatively more often used for clinical purposes. 
Colloidal silver was first approved for wound management by the US Food and Drug 
Administration (FDA) in the 1920s (59).  To date, silver compounds are still widely used in 
the treatment of open wounds due to the limited prescription of antibiotics.  Because of the 
widespread use of silver and copper as microcidal agents, concerns about the emergence of 
bacterial resistance are being raised (59, 60).  
The Cus system is encoded by a single operon cusCFBA, which is located on the E. 
coli chromosome (48, 49, 61).  The transcription of this operon is regulated by a two-
component system, consisting of a membrane kinase sensor (CusS) and a transcriptional 
regulatory responder (CusR) (62).  CusB and CusC are the MFP and OMP proteins, 
respectively. Presumably, in cooperation with the CusA efflux pump, they form a tripartite 
complex that spans both the inner and outer membranes of E. coli, resembling the AcrAB-
TolC system.  Distinct from most RND efflux complexes, the Cus system has an additional 
component - the small periplasmic protein CusF (63- 65).  The crystal structure of CusF 
depicts that this protein forms a five-stranded β–barrel with the conserved residues H36, W44, 
M47 and M49 making up the Cu(I)/Ag(I) binding site.  It has been proposed that CusF 
functions as a metallochaperone that delivers Cu(I) or Ag(I)
 
in the periplasm to the CusCBA 
efflux machinery.  The x-ray crystal structure of CusB has been solved recently in our lab 
(66).  The multiple Cu(I)/Ag(I) binding sites were discovered at the potential hinge regions 
between the individual domains.  One of the objectives of this dissertation is to understand 
the structure and function of the CusA inner membrane transporter, which is the most 
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important component of the Cus transport system.  I have determined the crystal structures of 
CusA in the absence and presence of Cu(I) and Ag(I).  Together with results from site-
directed mutagenesis and different biochemical assays, I put forward to propose a molecular 
mechanism that governs the heavy-metal export in bacteria.  It is expected that this 
information will provide us with important clues for the understanding of other HAE-RND 
efflux pumps. 
 
Organization of the dissertation 
Chapter 1 gives the general introduction of multidrug resistance in bacteria and of 
multidrug efflux pumps.  Two transporter families, including MATE and RND, are described 
in details.  The rationale of the dissertation is also addressed in this chapter.  Chapter 2 is a 
manuscript, published in Antimicrobial Agents and Chemotherapy in 2008, which 
characterizes two MATE transporters, N. gonorrhoeae NorM and E. coli YdhE. 
 Chapter 3 is a manuscript, submitted to the journal Nature, which describes the crystal 
structures of the HME-RND transporter CusA of E. coli in the absence and presence of Cu(I) 
and Ag(I).  In this chapter, a variety of functional studies were also performed to elucidate 
the molecular mechanisms of the efflux pump.  Chapter 4 summarizes the results and 
provides the overall conclusions of the dissertation.   
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Abstract 
Active efflux of antimicrobial agents is one of the most important adapted strategies 
that bacteria use to defend against antimicrobial factors that are present in their environment.  
The NorM protein of Neisseria gonorrhoeae and YdhE of Escherichia coli have been 
proposed to be multidrug efflux pumps that belong to the multidrug and toxic compound 
extrusion (MATE) family.  In order to determine their antimicrobial export capability, we 
cloned, expressed, and purified these two efflux proteins, and characterized their functions 
both in vivo and in vitro.  E. coli expressing norM or ydhE showed elevated (two-fold or 
greater) resistance to several antimicrobial agents, including fluoroquinolones, ethidium 
bromide, rhodamine 6G, acriflavin, crystal violet, barberine, doxorubicin, novobiocin, 
enoxacin, and tetraphenylphosphonium chloride.  When expressed in E. coli, both 
transporters reduced ethidum bromide and norfloxacin accumulation through a mechanism 
requiring the proton motive force and direct measurements of efflux confirmed that NorM 
behaves as a Na
+
-dependent transporter.  The capacity of NorM and YdhE to recognize 
structurally divergent compounds was confirmed using steady-state fluorescence polarization 
assays, and the results revealed that these transporters bind antimicrobials with dissociation 
constants (KD) in the micromolar region.  
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Introduction 
Neisseria gonorrhoeae is a gram-negative diplococcus, which is only found in 
humans and causes the sexually transmitted disease gonorrhea.  Since it is a strictly human 
pathogen and can colonize male and female genital mucosal surfaces and other sites, it has 
developed mechanisms to overcome host antimicrobial systems that are important in innate 
host defense.  One important mechanism that N. gonorrhoeae uses to subvert antimicrobial 
agents is the expression of multidrug efflux pumps that recognize and actively export a wide 
variety of toxic (often structurally unrelated) compounds, including antibacterial peptides, 
long-chain fatty acids, and several clinically useful antibiotics, from the bacterial cell (17, 34, 
36, 37).  
Recently, four efflux pumps have been identified in N. gonorrhoeae.  One such pump 
is the MtrD inner membrane protein (21) that exists as a component of the tripartite 
resistance nodulation cell division (RND) transporter (42).  MtrD interacts with a periplasmic 
membrane fusion protein, MtrC, and an outer membrane channel, MtrE, to mediate the 
export of hydrophobic antimicrobial agents, including antibiotics, nonionic detergents, 
certain antibacterial peptides, bile salts, and gonadal steroidal hormones (7, 9, 10, 37).  The 
FarB efflux pump (17), belonging to the major facilitator (MF) family (8, 22), recognizes 
antibacterial long-chain fatty acids and exports them out of the cell in conjunction with a 
membrane fusion protein FarA and the MtrE outer membrane protein channel (17).  The 
MacB transporter was recently described (33) and it belongs to the ATP binding cassette 
(ABC) transporter family (13).  It is poorly expressed in wild type gonococci due to a natural 
mutation in its promoter, but can recognize and export certain macrolide antibiotics.  Finally, 
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N. gonorrhoeae contains the NorM efflux pump (34), which is a member of the multidrug 
and toxic compound extrusion (MATE) family of efflux transporters (5, 25, 34).  The N. 
gonorrhoeae NorM transporter is homologous to the NorM efflux pump of Vibrio 
parahaemolyticus (25), the YdhE protein of Escherichia coli (2, 25, 43), VmrA of V. 
parahaemolyticus (6), and Vibrio cholerae VcrM (1, 27).  As a multidrug efflux pump, the 
gonococcal NorM appears to recognize a number of cationic toxic compounds, such as 
ethidium bromide, acriflavin, 2-N-methylellipticinium, and ciprofloxacin (34).  The capacity 
of NorM to export ciprofloxacin was suggested to be of clinical relevance in the development 
of fluoroquinolone resistance in N. gonorrhoeae especially when isolates have other 
mutations that raise the minimal inhibitory concentration (MIC) to a level near that seen in 
treatment failures. 
The MATE family transporters characteristically possess 12 putative transmembrane 
domains, and have been reported in all three kingdoms of life (Eukarya, Archaea, and 
Eubacteria) (5).  Phylogenetic tree analysis suggests that this family possesses three distinct 
clusters: (i) the bacterial multidrug efflux pumps, including N. gonorrhoeae NorM and E. 
coli YdhE; (ii) the eukaryotic efflux proteins found in fungi and plants, such as Erc1; and (iii) 
a branch containing E. coli DinF (5).  Among these three clusters, the putative NorM branch 
exhibits overall minimal identity and similarity of 26 and 47%. 
In order to directly test the capacity of the N. gonorrhoeae NorM pump to recognize 
putative substrates, including ciprofloxacin that was, until recently, widely used in the U.S. to 
treat gonococcal infections (15), we expressed the gonococcal norM gene in E. coli and 
investigated its function using drug susceptibility and transport assays.  We also studied the 
homologous protein YdhE in E. coli, and compared its function with that of N. gonorrhoeae 
20 
 
NorM.  Using a sensitive fluorescence polarization assay (12, 18), we characterized the 
interactions of these two transporters with various drugs.  The results revealed that NorM and 
YdhE bind a variety of structurally dissimilar agents in the micromolar range. 
 
Materials and Methods 
Cloning of norM and ydhE 
The norM ORF from genomic DNA of N. gonorrhoeae strain FA19 was amplified by 
PCR using the primers 5-GAGGAATAATAAATGCTGCTCGACCTCGACCGC-3 and 5-
GTTTAAACTCAATGGTGATGGTGATGATGGACGGCCTTGTGTGATTTGACC-3 to 
generate a product that would encode a NorM recombinant protein with a 6xHis tag at the C-
terminus (34).  The corresponding PCR product was extracted from the agarose gel and 
cloned into pBAD-TOPO as described by the manufacturer (Invitrogen).  To remove the V5 
epitope and polyhistidine region of the vector, the plasmid was digested with PmeI and then 
self-ligated to form the expression vector, pBADnorM.  The recombinant plasmid was 
transformed into DH5 cells and transformants were selected on LB agar plates containing 
100 g/ml ampicillin.  The presence of the correct norM sequence in the plasmid construct 
was verified by DNA sequencing. 
 Similarly, the ORF of ydhE from E. coli K12 genomic DNA was amplified by PCR 
and TA-cloned into pBAD-TOPO using the primers 5-
GAGGAATAATAAATGCAGAAGTATATCAGTG-3 and 5- 
GTTTAAACTCAATGGTGATGGTGATGATG GCGGGATGCTCGTTGCAGAATG-3 to 
21 
 
generate a PCR product that would encode a recombinant protein containing a 6xHis tag at 
the C-terminus.  The recombinant plasmid (pBADydhE) was transformed into DH5 cells 
as described above, and the presence of the correct insert in a representative plasmid 
transformant was verified by DNA sequencing. 
 
Drug susceptibility assays 
The MICs to various antimicrobial agents of E. coli strains (inoculum, 500 cells/ml) 
harboring pBADnorM, pBADydhE, or the pBAD vector were determined by the twofold 
dilution method using LB agar containing the desired antimicrobial agent (28).  Bacterial 
growth was recorded after18 to 24 h of incubation at 37℃.  Each assay was repeated at least 
four times to ensure the reproducibility of the results. 
 
Drug accumulation assays 
Assays of norfloxacin and ethidium bromide accumulations were performed as 
described previously (20, 24, 25).  In brief, E. coli AG100AX carrying pBADnorM, 
pBADydhE, or pBAD were grown in LB broth with 0.01% L-arabinose at 37oC to OD600 of 
1.0, harvested, washed with buffer containing 0.1 M Tris-HCl (pH 7.0) three times, and 
suspended in the same buffer to OD600 of 1.0. Norfloxacin was then added to a final 
concentration of 100 M. 1 ml samples were taken at intervals, centrifuged at 10,000 rpm for 
30 s at 4
o
C, and washed once with the same buffer.  After 15 min, carbonyl cyanide m-
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chlorophenylhydrazone (CCCP) was added to a final concentration of 100 M to disrupt the 
proton gradient across the membrane.  Then, 15 min later, CCCP was removed by 
centrifugation at 10,000 rpm for 30 s, and cells were resuspended with buffer containing 0.1 
M Tris-HCl (pH 7.0) and 0.4% glucose.  Each pellet was resuspended in 1 ml of 100 mM 
glycine-HCl (pH 3.0), shaken vigorously for 1 h at room temperature to release the 
fluorescent content, and then centrifuged at 15,000 rpm for 10 min at room temperature.  The 
fluorescence of supernatants was measured at ex and em of 277 and 448 nm, respectively, 
using a PerkinElmer LS55 spectrofluorometer equipped with a Hamamatsu R928 
photomultiplier.  The amount of maximum fluorescence was normalized to 100%. 
For ethidium bromide accumulation, cells were prepared similarly as above.  A final 
concentration of 20 g/ml of ethidium bromide was added to the cell suspension to initiate 
the assay.  1 ml samples were taken at different time points.  After 15 min of incubation, 
CCCP was added to a final concentration of 100 M.  Then, 15 min later, CCCP was 
removed by centrifugation at 10,000 rpm for 30 s, and cells were resuspended with buffer 
containing 0.1 M Tris-HCl (pH 7.0) and 0.4% glucose.  The fluorescence of samples was 
measured at ex and em of 500 and 580 nm, respectively (3).  The amount of maximum 
fluorescence was normalized to 100%. 
 
Accumulation of ethidium bromide in the presence of Na
+
 
E. coli AG100AX containing pBADnorM or pBAD were grown in LB broth with 
0.01% L-arabinose at 37
o
C to OD600 of 1.0, harvested by centrifugation, washed three times 
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with buffer containing 0.1 M Tris-HCl (pH 7.0), and suspended in the same buffer to OD600 
of 1.0.  Ethidium bromide was added to a final concentration of 20 g/ml to the cell 
suspension, followed by the addition of 100 mM NaCl or KCl.  At each time point, a 1 ml 
sample was removed, centrifuged at 10,000 rpm for 30 s at 4
o
C, and washed once with the 
same buffer.  The fluorescence signal was measured at ex and em of 500 and 580 nm, 
respectively. 
 
Efflux of norfloxacin in the presence of Na
+
 
For determining norfloxacin efflux, cells were grown in LB broth with 0.01% L-
arabinose at 37
o
C to OD600 of 1.0, harvested, and washed twice with buffer containing 0.1 M 
Tris-HCl (pH 7.0).  To load cells with norfloxacin, bacteria were incubated in the same 
buffer supplemented with 100 M norfloxacin and 20 M CCCP at 37oC for 30 min as 
described previously (31).  Cells were then pelleted, washed twice, and resuspended with the 
same buffer to OD600 of 2.0.  1 ml samples were taken at intervals, centrifuged at 10,000 rpm 
for 30 s at 4
o
C, and washed once with the same buffer. After 10 min, NaCl or KCl was added 
to a final concentration of 100 M.  Fluorescence measurement of norfloxacin was 
performed by a similar procedure as described above.    
 
Purification of the transporters   
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The N. gonorrhoeae NorM protein containing a 6xHis tag at the C-terminus was 
overproduced in E. coli TOP10 cells (Invitrogen) possessing pBADnorM. Cells were 
grown in 12 L of LB medium with 100 g/ml ampicillin at 37oC.  When the OD600 reached 
0.5, the culture was treated with 0.2% L-arabinose to induce norM expression and harvested 
within 3 h.  The collected bacteria were resuspended as described (44) in low salt buffer 
containing 100 mM sodium phosphate (pH 7.2), 10 % glycerol, 1 mM EDTA and 1 mM 
phenylmethanesulfonyl fluoride (PMSF), and then disrupted with a French pressure cell.  The 
membrane fraction was collected and washed twice with high salt buffer containing 20 mM 
sodium phosphate (pH 7.2), 2 M KCl, 10 % glycerol, 1 mM EDTA and 1 mM 
phenylmethanesulfonyl fluoride (PMSF), and once with 20 mM HEPES-NaOH buffer (pH 
7.5) containing 1 mM PMSF.  The membrane protein was then solubilized in 1 % (w/v) n-
dodecyl--D-maltoside (DDM).  Insoluble material was removed by ultracentrifugation at 
370,000 x g.  The extracted protein was loaded into a Ni
2+
-affinity column, washed with 
buffer containing 20 mM HEPES-NaOH (pH 7.5), 50 mM imidazole and 0.02% DDM, and 
eluted with buffer consisting of 20 mM HEPES-NaOH (pH 7.5), 400 mM imidazole and 0.02% 
DDM.  The eluted protein was then concentrated to 5 mg/ml and loaded into a G-200 sizing 
columns pre-incubated with 20 mM HEPES-NaOH (pH 7.5) and 0.02% DDM for further 
purification.  The YdhE protein that contains a 6xHis tag at the C-terminus was 
overproduced in E. coli TOP10 pBADydhE and purified as described above for NorM.  
The purity (>90%) of the NorM and YdhE proteins were judged using 10% SDS-PAGE 
stained with Coomassie Brilliant Blue. 
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Fluorescence polarization assays  
Fluorescence polarization assays (12, 18) were used to determine the drug binding 
affinities of NorM and YdhE, respectively.  The experiments were done using a ligand 
binding solution containing 20 mM HEPES-NaOH (pH 7.5), 0.02% DDM, and 1 M ligand 
(rhodamine 6G, ethidium, proflavin, ciprofloxacin, or norfloxacin).  The protein solution 
consisting of NorM or YdhE in 20 mM HEPES-NaOH (pH 7.5), 0.02% DDM, and 1 M 
ligand was titrated into the ligand binding solution until the polarization (P) was unchanged.  
As this is a steady-state approach, fluorescence polarization measurement was taken after a 5 
min incubation for each corresponding concentration of the protein and drug to ensure that 
the binding has reached equilibrium.  It should be noted that the detergent concentration was 
kept constant at all times to eliminate the change in polarization generated by drug-DDM 
micelle interaction.  All measurements were performed at 25
o
C using a PerkinElmer LS55 
spectrofluorometer equipped with a Hamamatsu R928 photomultiplier. The excitation 
wavelengths were 527, 483, 447, 330, and 277 nm, respectively, for rhodamine 6G, ethidium, 
proflavin, ciprofloxacin, and norfloxacin.  Fluorescence polarization signals (in P) were 
measured at emission wavelengths of 550, 620, 508, 415, and 448 nm, respectively, for these 
ligands.  Each titration point recorded was an average of 15 measurements.  Data were 
analyzed using the equation, P = {(Pbound – Pfree)[protein]/(KD + [protein])} + Pfree, where P is 
the polarization measured at a given total protein concentration, Pfree is the initial polarization 
of free ligand, Pbound is the maximum polarization of specifically bound ligand, and [protein] 
is the protein concentration.  The titration experiments were repeated for three times to obtain 
the average KD value.  Curve fitting was accomplished using the program ORIGIN (30). 
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Results and Discussion 
Drug specificity of NorM and YdhE in vivo 
To determine if the N. gonorrhoeae NorM multidrug transporter is functionally 
expressed in E. coli, and to compare its activity to a second member (YdhE) of the MATE 
family of efflux pumps, we transformed the E. coli AG100AX, an AcrAB-deficient strain (29) 
with the empty pBAD vector, pBADnorM, or pBADydhE.  We then tested the 
susceptibility of the representative transformants bearing these plasmids to a panel of 24 
structurally divergent antimicrobials (Table 1).  These antimicrobials were selected based on 
whether or not they are putative substrates of MATE family exporters in the NorM subclass.  
It is important to stress that in many instances expression of drug efflux pumps, including 
members of the MATE superfamily (5), can have only modest changes (two-fold) in bacterial 
susceptibility to certain antimicrobials while more significant changes in susceptibility to 
other agents can be observed in the same system.  Indeed, in our drug testing experiments we 
detected a range of changes in the susceptibility of E. coli cells producing either NorM or 
YdhE.   
Of the 24 antimicrobials tested, the AG100AX cells expressing the N. gonorrhoeae 
NorM were less sensitive (two- to eight-fold) than AG100AX cells containing pBAD to a 
subset of antibiotics (norfloxacin, doxurubicin, novobiocin, lomefloxacin, enoxacin and 
ciprofloxacin), dyes (rhodamine 6G, ethidium bromide, acriflavine and crystal violet) and 
quartenary ammonium compounds (berberine, benzalkonium and tetraphenylphosphonium 
chloride).  The YdhE-producing cells displayed a similar drug susceptibility profile (with the 
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exception of lomefloxacin) as that of the NorM-producing E. coli cells, suggesting that these 
two MATE transporters are functionally similar in vivo.  
Like YdhE of E. coli, our drug susceptibility experiments showed that NorM 
functions as a multidrug efflux pump when expressed in E.coli.  The MICs to 14 of the 24 
antimicrobials (Table 1) were observed to increase by two- to eight-fold in NorM-producing 
AG100AX bacteria, which lacks the AcrB efflux pump.  Similar differences (data not 
presented) in antimicrobial susceptibility were obtained in AcrB
+
 E. coli TOP10 cells that 
were used to obtain recombinant NorM.  In that the MICs of norfloxacin, ciprofloxacin, 
enoxacin, lomefloxacin were raised in cells expressing NorM or YdhE, our results suggest 
that like other MATE transporters, such as BexA of B. thetaiotaomicron (23), VcmA of 
Vibrio cholerae (16), NorM of Vibrio cholerae (38) and AbeM of Acinetobacter baumannii 
(41), fluoroquinolones might be a common substrate for MATE transporters in the NorM 
cluster. 
 
NorM and YdhE reduce drug accumulation in bacteria     
The observed (Table 1) capacity of NorM and YdhE to reduce the susceptibility of E. 
coli to norfloxacin, ciprofloxacin and ethidium bromide is consistent with the drug 
recognition profile of other members of the MATE efflux transporter family.  To confirm the 
drug susceptibility testing results, we measured the accumulation of norfloxacin and ethidum 
bromide in AG100AX cells that carried pBADnorM, pBADydhE, or pBAD.  The results 
showed lower levels of norfloxacin (Figure 1a) or ethidum bromide (Figure 1b) accumulation 
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in AG100AX cells producing NorM or YdhE compared to control cells harboring the empty 
pBAD vector.   
Members of the MATE family use energy from the proton motive force (PMF) during 
export and loss of the PMF inactivates pump activity resulting in enhanced accumulation of 
substrates, which translates to increased susceptibility to the agents normally recognized by 
the transporter.  Accordingly, we also measured norfloxacin and ethidium bromide 
accumulation after addition of CCCP, a de-coupler of the membrane proton gradient.  After 
the addition of CCCP into the assay solution, the accumulation of norfloxacin (Figure 1a) 
and ethidum bromide (Figure 1b) increased drastically in the NorM- and YdhE- expressing 
cells, with the levels of accumulation being nearly the same in the three different strains 
within 5 min.  It should be noted that the effect of CCCP is reversible simply by removing 
CCCP and adding glucose to re-energize AG100AX cells.  The experiments were performed 
at least three times.  Statistical comparisons were assessed by Student‟s t test, and P values of 
< 0.05 were considered statistically significant differences (Figure 1a and b).   
 
NorM expressed in E. coli behaves as a Na
+
 ion-dependent transporter   
It has been suggested but not proven that NorM of N. gonorrhoeae is a Na
+
-drug 
antiporter (34).  Thus, we investigated the accumulation of ethidium bromide in isogenic 
strains AG100AX/pBADnorM and AG100AX/pBAD in the presence of Na+ or K+.  In 
AG100AX/pBADnorM cells, a lower level of ethidum bromide accumulation was 
observed in the presence of 100 mM NaCl when compared to that in the presence of 100 mM 
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KCl (Figure 2a).  In contrast, we did not observe a difference in ethidum bromide 
accumulation in AG100AX/pBAD regardless of the presence of NaCl or KCl (Figure 2b).  
Furthermore, in the presence of NaCl the accumulation level of ethidium bromide in the 
NorM-producing strain was lower than that in AG100AX/pBAD.   
We next measured the efflux of norfloxacin that had accumulated in strains 
AG100AX/pBADnorM or AG100AX/pBAD, respectively, in the presence of Na+ or K+.  
Cells were first loaded with norfloxacin, thereafter, 100 mM of either NaCl or KCl was 
added to test the effect on drug efflux.  As shown in Figure 3a, the addition of 100 mM NaCl 
to AG100AX/pBADnorM cells resulted in greater efflux of the drug from cells compared 
to that observed in the presence of KCl or without added salt.  This effect was NorM-
dependent because the addition of either NaCl (100 mM) or KCl (100 mM) to 
AG100AX/pBAD cells did not impact norfloxacin efflux (Figure 3b).  Taken together with 
the ethidum bromide accumulation results, our observations support the earlier proposal (34) 
that the gonococcal NorM protein is a Na
+
-dependent transporter. 
In order to directly test whether efflux of an antimicrobial by NorM is Na
+
-dependent, 
we then studied the extrusion of norfloxacin that has been accumulated in 
AG100AX/pBADnorM in the presence of CCCP.  Cells were first loaded with norfloxacin.  
Thereafter, different concentrations of NaCl (50-200 mM) were added to test the effect on 
drug efflux.  All these tests were done in the presence of 20 M CCCP.  If NorM requires 
proton ion as a coupler, then the accumulated level of norfloxacin in cell should not be 
reduced under these conditions.  However, if the coupling ion is Na
+
, we should be able to 
observe norfloxacin efflux in a [Na
+
]-dependent manner.  Figure 4 depicts the effect of Na
+
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on the extrusion of norfloxacin.  The experiment suggests that efflux activity was stimulated 
by Na
+
 ion.  The addition of NaCl resulted in a significant change in norfloxacin efflux.  
Previous study in Pseudomonas aeruginosa PmpM, an H
+
-dependent transporter in the 
MATE family, indicated that Na
+
 ion has no effect on drug transport (11).  Thus, it is highly 
likely that Na
+
 is the coupling cation for NorM.             
Our drug accumulation and efflux assays confirm the earlier report which suggested 
that NorM of N. gonorrhoeae is a Na
+
/drug antiporter (34).  First, Na
+
 was found to enhance 
the ability of E. coli producing NorM to maintain a lower accumulation level of ethidium 
bromide as compared to those cells not producing NorM, even in the presence of Na
+
 (Figure 
2).  Hence, drug export mediated by NorM of N. gonorrhoeae is driven by Na
+
 gradient.  
This export mechanism is also influenced by the integrity of the PMF of the cytoplasmic 
membrane since CCCP, a proton conductor, could significantly enhance the accumulation 
level of ethidium bromide in NorM-producing bacteria.  These accumulation assays provide, 
however, indirect evidence for efflux.  Accordingly, direct support for efflux was obtained in 
experiments that measured norfloxacin export by NorM-producing E. coli.  The observed 
Na
+
-dependent capacity of NorM to mediate export of norfloxacin (Figures 3 and 4) provides 
direct evidence for this model.   
 
Binding affinities of different drugs in vitro 
The in vivo antimicrobial susceptibility testing (Table 1) and accumulation/efflux 
studies (Figures 1-4) suggested that NorM and YdhE recognize and export structurally 
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diverse compounds.  There is, however, little known about the detail of substrate binding by 
these MATE transporters.  In order to directly test the capacity of these proteins to bind such 
diverse compounds, we used a fluorescence polarization assay to quantify the binding 
affinities of several compounds to NorM and YdhE in vitro.  This technique has been found 
to be sensitive and precise enough, and allow us for the first time, to detect ligand binding of 
the E. coli AcrB multidrug efflux pump (an RND transporter) in a detergent environment 
(40).  As an example of the results obtained by this protocol, Figure 5a illustrates the binding 
isotherm of NorM in the presence of rhodamine 6G.  As presented in the figure, a simple 
hyperbolic curve was observed for the binding of rhodamine 6G with a dissociation constant, 
KD, of 3.4  0.2 M.  A Hill plot of the data yielded a Hill coefficient of 1.01  0.03 (Figure 
5b), suggesting a simple drug binding process with a stoichiometry of one NorM monomer 
per rhodamine 6G ligand.  When the data were presented as a Scatchard plot (not shown), it 
indicated a similar KD of 3.6  0.1 M with no sign of heterogeneity in binding sites.  In 
addition, the titration experiments indicated that YdhE binds rhodamine 6G with a KD of 3.0 
 0.2 M (Figure 6a).  This value is comparable with that of NorM, suggesting that these two 
transporters share similar affinity for this ligand. The Hill (Figure 6b) and Scatchard (not 
shown) plots of the data indicated that the transporter employs a simple binding 
stoichiometry of 1:1 monomeric YdhE-to-rhodamine 6G molar ratio. 
Fluorescence polarization assays were also employed to elucidate the interaction of a 
variety of drugs with the NorM and YdhE transporters.  The titration experiments indicated 
that NorM binds ethidium bromide, proflavin, ciprofloxacin, and norfloxacin with 
dissociation constants of 12.3  1.3 M, 33.6  1.9 M, 121.3  15.7 M, and 105.6  9.8 
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M, respectively (Table 2).  These values are in the same range with those of YdhE, which 
binds ethidium bromide, proflavin, ciprofloxacin and norfloxacin with KD values of 9.8  0.9 
M, 22.1  0.9 M, 90.9  12.4 M, and 98.4  16.2 M, respectively (Table 2).  This 
binding was not impacted by detergent since similar dissociation constants for the rhodamine 
6G-YdhE complex were obtained in reaction mixtures that included 0.2%, 0.02% and 0.0075% 
DDM. 
To verify the validity of the fluorescence polarization assay, we studied the binding 
affinity of rhodamine 6G with the purified, detergent-solubilized YdhE efflux pump using 
equilibrium dialysis.  The dialysis data suggest a KD of 3.0  0.1 M, with a stoichiometry of 
1:1 monomeric YdhE-to-ligand molar ratio, for the binding of YdhE with rhodamine 6G (see 
Suppl. Fig. S1).  This result is in good agreement with that observed from fluorescence 
polarization in which the KD of YdhE-rhodamine 6G is 3.0 M with a 1:1 binding 
stoichiometry.  Apparently, NorM and YdhE bind these drugs with similar affinities.  These 
values are similar to the KD values for tetraphenylphosphonium binding in MdfA, a MF 
transporter, and EmrE, a SMR transporter, determined by radiolabeled binding assays (19, 
26), as well as the most recently determined dissociation constants for AcrB, an RND 
transporter, with four different ligands using fluorescence polarization assays (40). 
The results from fluorescence polarization and equilibrium dialysis assays suggest 
that NorM and YdhE use a binding stoichiometry of 1:1 monomeric transporter-to-ligand 
ratio.  Thus, it is very likely that these transporters employ a simple drug binding process 
with no cooperativity.  There is, however, a possibility that drug molecules may bind to more 
than one site in the proteins, with similar affinities, that may not be able to be distinguished 
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using these techniques.  Further experiments utilizing different approaches may need to 
confirm this drug binding stoichiometry.  
 
pH dependence of drug binding to NorM 
We performed fluorescence polarization experiments to determine the binding of 
rhodamine 6G to NorM at different pH values.  Figure 7 illustrates the decrease in KD values 
for rhodamine 6G as the pH increases from 5.8 to 8.5.  Within this pH range, the KD value 
decreases by about 2.6 M.  This change is quite modest when compared with the effect of 
proton on the PMF-dependent efflux pumps, E. coli AcrB (40) and EmrE (26).  The binding 
affinities for drugs in these two transporters were strikingly dependent on pH.  In the case of 
AcrB, within the range of pH from 5.5 to 8.4, fluorescence polarization assay suggests that 
the change in KD for AcrB-rhodamine 6G reached 10.3 M.  As NorM shows a very different 
pH-dependent profile compared with those of the PMF-dependent pumps AcrB and EmrE, it 
is very likely that NorM does not use H
+
 as an energy-coupling ion.  Since NorM tends to 
bind positively charged drugs, we expect that its drug-binding pocket should consist of at 
least one acidic residue.  Indeed, the protein sequence of NorM suggests that this transporter 
consists of two negatively charged residues, Glu 261 and Asp 377, in the transmembrane 
region.  These acidic residues potentially could form the multidrug binding site. Thus, the 
modest pH effect on NorM could be accounted for the protonation state of the acid residue(s) 
in the binding pocket. 
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Na
+
 dependence of drug binding to NorM 
As in vivo studies of drug accumulation and efflux suggest, NorM is a Na
+
-dependent 
transporter, the presence of Na
+
 ions may affect the drug binding affinity in vitro.  We 
therefore investigated the Na
+
 dependence of drug binding using fluorescence polarization.  
As shown in Figure 8, the KD for rhodamine 6G is Na
+
 dependent when the concentration of 
Na
+
 is in the sub-micromolar range.  In this region, the dissociation constant for rhodamine 
6G was a simple hyperbolic function of the Na
+
 concentration.  The curve showed 
saturability over 0.01 to 100 mM.  Like the pH effect, the change in KD for rhodamine 6G 
due to the presence of Na
+
 ion is quite small.  Within 0 to 100 mM Na
+
, the change in KD 
only reached 2.5 M (Figure 8).  We also added various concentrations of NaCl ranging from 
100 to 400 mM (data not shown) and observed no significant change in the KD.  
 
Competition binding of different drugs in YdhE  
To confirm that the drug molecules bind specifically in these transporters, we 
performed competition experiments in which tetraphenylphosphonium chloride (TPP) was 
titrated into a solution containing the preformed YdhE-rhodamine 6G complex.  In this case, 
TPP was chosen as a second ligand to knock off the bound rhodamine 6G from YdhE.  The 
absorption spectra of TPP (from 200 to 600 nm) showed that this molecule absorbs light at 
the wavelengths of 224.9, 268.0 and 275.9 nm.  At  = 527 nm, which is the excitation 
wavelength for rhodamine 6G, the energy is too low to excite TPP.  Thus, TPP was treated as 
a non-fluorescent ligand in the “knock off” experiments.  The data revealed that TPP was 
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able to bind YdhE and replace the bound rhodamine 6G molecule from the protein as 
demonstrated by the release of rhodamine 6G observed from the reduction of polarization 
(Figure 9).  This binding assay provides direct evidence that TPP interferes with the binding 
of rhodamine 6G, possibly by a direct competitive binding process for the same binding site.  
Alternatively, the release of rhodamine 6G by TPP may be due to an allosteric interaction 
between distinct binding sites of these two ligands.  Regardless, the titrations demonstrate 
that rhodamine 6G is bound specifically in the YdhE transporter. 
We have determined the binding affinities of five different drugs to the purified, 
detergent-solubilized NorM and YdhE proteins, respectively, using fluorescence polarization 
assays.  We note that fluorescence polarization has been widely used for studying protein-
DNA interaction (12, 14, 18), and protein-ligand interaction in transcriptional regulators (4, 
35, 39).  To our knowledge, this is the first attempt using this methodology to investigate 
interaction between MATE proteins and their transported substrates.  This approach also 
allows us, for the first time, to quantify the strength of transporter-drug interaction among the 
MATE family of transporters. 
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Tables 
Table 1.  Drug susceptibility. 
 MIC (g/ml) 
Drug 
AG100AX/ 
pBADnorM 
AG100AX/ 
pBADydhE 
AG100AX/pBAD 
Ethidium bromide 15.63 15.63 7.81 
Ciprofloxacin 0.006 0.006 0.003 
Rhodamine 6 G 12.5 12.5 3.125 
Chloramphenicol 0.625 0.625 0.625 
Tetraphenyl-
phosphonium chloride 
25 25 12.5 
Norfloxacin 0.032 0.016 0.008 
Ofloxacin 0.013 0.013 0.013 
Lomefloxacin 0.032 0.016 0.016 
Tetracycline 1.25 1.25 1.25 
Enoxacin 0.063 0.063 0.031 
Doxorubicin 6.25 6.25 1.56 
Benzalkonium 0.625 0.312 0.156 
Novobiocin 3.125 3.125 1.56 
Nalidixic acid 0.625 0.625 0.625 
Crystal violet 2.5 2.5 0.625 
Carbonyl cyanide m-
chlorophenylhydrazone 
6.25 6.25 6.25 
Rifampin 6.25 6.25 6.25 
Streptomycin >50,000 >50,000 >50,000 
Methyl viologen 156.3 156.3 156.3 
Vancomycin 250 250 250 
Minocycline 0.625 0.625 0.625 
Berberine 250 250 31.25 
Acriflavine 7.82 7.82 3.91 
Proflavin 12.5 12.5 6.25 
Gentamicin 2.5 2.5 2.5 
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Table 2.  Dissociation constants and Hill coefficients of NorM and YdhE with five different 
transported drugs. 
 
Drug 
NorM YdhE 
KD (μM) Hill coefficient KD (μM) Hill coefficient 
Rhodamine 6G 3.4 ± 0.2 1.01 ± 0.03 3.0 ± 0.2 1.00 ± 0.04 
Ethidium 12.3 ± 1.3 0.96 ± 0.05 9.8 ± 0.9 0.97 ± 0.05 
Profloxacin 33.6 ± 1.9 0.94 ± 0.03 22.1 ± 0.9 1.02 ± 0.01 
Ciprofloxacin 121.3 ± 15.7 1.08 ± 0.06 90.9 ± 12.4 1.09 ± 0.06 
Norfloxacin 126.3 ± 11.3 1.06 ± 0.03 98.4 ± 16.2 1.14 ± 0.05 
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Figures and Captions 
 
 
Figure 1.  NorM and YdhE reduce accumulation of norfloxacin and ethidium bromide in E. 
coli cells. (a) Accumulation of norfloxacin in cells transformed by NorM 
(AG100AX/pBADnorM), YdhE (AG100AX/pBADydhE), or empty vector 
(AG100AX/pBAD). CCCP was added to the suspensions (first arrow) at a final 
concentration of 100 M. After 15 min, glucose was added (second arrow) at a final 
concentration of 0.4%.  (b) Accumulation of ethidium bromide in the same strains. CCCP 
was added to the suspensions (first arrow) at a final concentration of 100 M. After 15 min, 
glucose was added (second arrow) at a final concentration of 0.4%. “*” indicates values of 
AG100AX/pBADnorM and AG100AX/pBADydhE cells that are significantly different 
from the control (AG100AX/pBAD) values (P < 0.05). 
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Figure 2.  Sodium ion reduces accumulation of ethidium bromide in cells transformed by 
NorM. (a) Accumulation of ethidium bromide in AG100AX/pBADnorM after the addition 
of 100 mM NaCl or KCl. (b) Accumulation of ethidium bromide in AG100AX/pBAD 
(carrying the empty vector) after the addition of 100 mM NaCl or KCl. “*” indicates values 
of ethidium fluorescence intensity in the presence of 100 mM NaCl that are significantly 
different from those in the presence of 100 mM KCl (P < 0.01). 
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Figure 3.  Sodium ion enhances norfloxacin efflux via NorM. (a) Norfloxacin efflux from 
AG100AX/pBADnorM cells carrying the norM gene from N. gonorrhoeae. (b) 
Norfloxacin efflux from AG100AX/pBAD cells carrying the empty vector. NaCl or KCl was 
added to the suspensions (arrow) at a final concentration of 100 mM. “*” indicates values of 
norfloxacin fluorescence in the presence of 100 mM NaCl that are significantly different 
from those in the presence of 100 mM KCl (P < 0.05). 
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Figure 4.  Effect of Na
+
 concentration on norfloxacin extrusion via NorM.  Norfloxacin 
efflux from AG100AX/pBADnorM cells carrying the norM gene in the presence of 0 to 
200 mM NaCl. “*” indicates values of norfloxacin fluorescence in the presence of 50, 100 or 
200 mM NaCl that are significantly different from those without NaCl (P < 0.003), as well as 
values of norfloxacin fluorescence in the presence of 100 or 200 mM NaCl that are 
significantly different from those in the presence of 50 mM NaCl (P < 0.01). 
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Figure 5.  Representative fluorescence polarization of NorM in 0.02% DDM with rhodamine 
6G. (a) Binding isotherm of NorM with rhodamine 6G, showing a KD of 3.4  0.2 M, in 
buffer containing 20 mM Tris (pH 7.5) and 0.02% DDM. (b) Hill plot of the data obtained 
for rhodamine 6G binding to NorM.  corresponds to the fraction of bound rhodamine 6G. 
The plot gives a slope of 1.01  0.03, indicating a simple binding process with no 
cooperativity. The interception of the plot provides a KD of 3.6  0.1 M for the rhodamine 
6G binding. 
  
49 
 
 
Figure 6.  Representative fluorescence polarization of YdhE in 0.02% DDM with rhodamine 
6G. (a) Binding isotherm of YdhE with rhodamine 6G, showing a KD of 3.0  0.2 M, in 
buffer containing 20 mM Tris (pH 7.5) and 0.02% DDM. (b) Hill plot of the data obtained 
for rhodamine 6G binding to YdhE.  corresponds to the fraction of bound rhodamine 6G. 
The plot gives a slope of 1.00  0.04, indicating a simple binding process with no 
cooperativity. The interception of the plot provides a KD of 3.6  0.2 M for the rhodamine 
6G binding. 
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Figure 7.  Effect of pH on the KD of rhodamine 6G binding to NorM. The resulting KDs were 
plotted against pH. 
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Figure 8.  Effect of Na
+
 concentration on the KD of rhodamine 6G binding to NorM. The 
resulting KDs were plotted against NaCl concentration. 
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Figure 9.  YdhE binding competition experiment between rhodamine 6G and 
tetraphenylphosphonium chloride (TPP).  YdhE (5 M) was pre-incubated with rhodamine 
6G (1 M) for two hours before titration.  The change in fluorescence polarization signals 
(FP) of rhodamine 6G was measured at an emission wavelength of 550 nm.  TPP was non-
fluorescent in the experimental conditions.  The decrease in FP showed that the bound 
rhodamine 6G was knocked off by TPP. 
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 Supplemental material 
 
 
Figure S1. Scatchard plot of equilibrium dialysis data for YdhE binding to rhodamine 
6G. The YdhE-rhodamine 6G dialysis experiments were carried out with 2-5 µM 
monomeric YdhE dialyzed against 3-5 µM rhodamine 6G. The slope of the plot provides 
a KD of 3.0 ± 0.1, and the interception (1.0 ± 0.2) gives a stoichiometry of 1:1 monomeric 
YdhE-to-R6G molar ratio. 
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CHAPTER 3.  Crystal structures of the CusA heavy-metal efflux pump 
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Gram-negative bacteria, such as Escherichia coli, frequently utilize tripartite efflux 
complexes in the resistance-nodulation-division (RND) family to expel diverse toxic 
compounds from the cell.
1,2
  One such efflux system CusCBA is responsible for 
extruding biocidal Cu(I) and Ag(I) ions.
3,4
  As no structural information is available for 
the heavy-metal efflux (HME) subfamily of the RND efflux pumps, we here describe the 
crystal structures of the inner membrane transporter CusA in the absence and presence 
of bound Cu(I) or Ag(I).  The CusA structures reported here provide important new 
structural information about the HME subfamily of RND efflux pumps.  The structures 
suggest that the metal binding sites, formed by a three-methionine cluster, are located 
within the cleft region of the periplasmic domain.  Intriguingly, this cleft is closed in the 
apo-CusA form but open in the CusA-Cu(I) and CusA-Ag(I) structures, which directly 
suggests a plausible pathway for ion export.  The binding of Cu(I) and Ag(I) triggers 
significant conformational changes in both the periplasmic and transmembrane 
domains.  The crystal structure indicates that CusA has, in addition to the three-
methionine metal binding site, five methionine pairs - three located in the 
transmembrane region and two in the periplasmic domain.  Genetic analysis and 
transport assays suggest that CusA is capable of actively picking up metal ions from the 
cytosol, utilizing five of these methionine pairs/clusters to bind and export metal ions.  
We propose a stepwise shuttle mechanism for transport between these sites.      
Silver is a heavy metal with a relatively high toxicity in prokaryotes.  Ionic silver 
exhibits antimicrobial activity against a broad range of microorganisms, and has long been 
used as an effective broad antimicrobial agent against pathogens.
5,6
  Copper, although 
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required in trace amounts for bacterial growth, is highly toxic even at low concentrations.
7
  
Thus, both silver and copper are well-known bactericides, and their biocidal effects have 
been used for centuries.  In Gram-negative bacteria, efflux systems of the resistance-
nodulation-division (RND) superfamily play major roles in the intrinsic and acquired 
tolerance of antibiotics and toxic compounds, including silver and copper ions.
1,2
  The Gram-
negative bacterium Escherichia coli harbors seven different RND efflux transporters.  These 
transporters can be categorized into two distinct sub-families, the hydrophobic and 
amphiphilic efflux RND (HAE-RND) and heavy-metal efflux RND (HME-RND) families.
1,2
  
Six of these transporters, such as AcrB, AcrD, AcrF, MdtB, MdtC and YhiV, are multidrug 
efflux pumps, which belong to the HAE-RND protein family.
1
  In addition to these multidrug 
efflux pumps, E. coli contains one HME-RND efflux transporter, CusA, which specifically 
recognizes and confers resistance to Ag(I) and Cu(I) ions.
3,4
  The two sub-families of these 
RND transporters share relatively low protein sequence homology.  For example, sequence 
alignment shows that CusA and AcrB have only 19% identity. 
As a RND transporter, CusA works in conjunction with a periplasmic component, 
belonging to the membrane fusion protein family, and an outer membrane channel to form a 
functional protein complex.  CusA is a large proton motive force-dependent inner membrane 
efflux pump comprised of 1,047 amino acids.
3,4
  CusC, however, is a 457 amino acid protein 
that forms an outer membrane channel.
3,4
  The membrane fusion protein CusB (379 amino 
acids) contacts both the inner membrane CusA and outer membrane CusC proteins.
3,4
  
Presumably, the three components of this HME-RND system form a tripartite efflux complex 
CusCBA, which spans both the inner and outer membranes of E. coli to export Ag(I) and 
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Cu(I) directly out of the cell.  Heavy-metal efflux by the CusCBA complex is driven by 
proton import, and this process is catalyzed through the inner membrane transporter CusA. 
At present, only two crystal structures of RND-type efflux pumps are available.  
These efflux pumps, belonging to the HAE-RND subfamily, are the E. coli AcrB
8-12
 and 
Pseudomonas aeruginosa MexB
13
 multidrug transporters.  Their structures suggest that both 
AcrB and MexB span the entire width of the inner membrane and protrude approximately 
70Å into the periplasm.  Along with the models of these two HAE-RND transporters, the 
crystal structures of the other components of these tripartite complex systems have also been 
determined.  These include the outer membrane channels, E. coli TolC
14
 and P. aeruginosa 
OprM,
15
 as well as the periplasmic membrane fusion proteins, E. coli AcrA
16
 and P. 
aeruginosa MexA.
17-19
  
Currently, no structural information has yet been available for any HME-RND type 
efflux pump.  Several attempts at crystallizing the CusA efflux pump have not succeeded, 
probably because of the flexible nature of this pump.
20,21
  Presumably, the three components 
of this HME-RND system form a tripartite complex that resembles the AcrAB-TolC complex.  
Different from the HAE-RND family, members of the HME-RND family are highly 
substrate-specific, with the ability to differentiate between monovalent and divalent ions.  To 
elucidate the mechanism used by the CusCBA efflux system for Cu(I)/Ag(I) recognition and 
extrusion, we have previously reported the crystal structure of the full-length CusB 
membrane fusion protein.
22
  Now we describe the crystal structure of the HME-RND 
transporter CusA, both in the absence and presence of Cu(I) or Ag(I).  The structures 
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strongly suggest that CusA relies upon methionine residues to bind and export the metal ions, 
as has been proposed.
4 
We cloned, expressed and purified the full-length CusA protein containing a 6xHis 
tag at the N-terminus.  We obtained crystals of the E. coli CusA heavy-metal efflux pump 
following an extensive screening for crystallization conditions with different detergents.  We 
then used multiple-isomorphous replacement with anomalous scattering (MIRAS) to 
determine the three-dimensional structure.  The diffraction data can be indexed to the space 
group R32.  Data collection and refinement statistics are summarized in Tables S1 and S2.  
The resulting experimental electron density maps (Fig. S1) reveal that the asymmetric unit 
consists of one protomer.  The native crystal structure of CusA has been determined to a 
resolution of 3.52 Å (Table S1).  Currently, 97.9% of the residues (residues 5-504 and 516-
1040) are included in our final model.  The final structure is refined to Rwork and Rfree of 23.7% 
and 27.9%, respectively.  
Overall, the crystal structure of CusA is quite distinct from those of the HAE-RND 
pumps, AcrB and MexB.  Superimposition of the structure of CusA with the structure of 
AcrB (pdb code:1IWG)
8
 results in a high RMSD of 11.4 Å for 1,003 C

 atoms, suggesting 
highly significant differences between these two transporters.  CusA exists as a homotrimer, 
and each subunit of CusA consists of 12 transmembrane helices (TM1-TM12) and a large 
periplasmic domain formed by two periplasmic loops between TM1 and TM2, and TM7 and 
TM8, respectively (Fig. 1 and Fig. S2).  In the transmembrane region, the relative locations 
of TM1-TM6 are related to those of TM7-TM12 by pseudo-twofold symmetry.  These TM 
helices are arranged in such a way that TM4 and TM10 form the center of the core and are 
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surrounded by the other TM helices.  Differently from AcrB and MexB, four helices, TM4, 
TM5, TM10 and TM11, extend into the cytoplasm, forming the cytoplasmic domain of the 
pump.  Two other helices, TM2 and TM8, protrude into the periplasm and contribute part of 
the periplasmic domain.  It is important to note that TM2, TM4 and TM5 of the N-terminal 
half correspond to TM8, TM10 and TM11 of the C-terminal half, respectively, in the pseudo-
twofold symmetry.  
Like AcrB and MexB, the periplasmic domain of CusA can be divided into six sub-
domains, PN1, PN2, PC1, PC2, DN and DC (Fig. 1).  Sub-domains PN1, PN2, PC1 and PC2 
form the pore domain, with PN1 making up the central pore and stabilizing the trimeric 
organization.  Sub-domains DN and DC, however, contribute to form the docking domain, 
presumed to be interacting with the outer membrane channel CusC.  The trimeric CusA 
structure suggests that sub-domains PN2, PC1 and PC2 are located at the outermost core of 
the periplasmic domain, facing the periplasm.  In AcrB, sub-domains PC1 and PC2 form a 
large external cleft and are presumed to create the entrance for drugs from the periplasm.  
However, the apo-CusA structure shows that the gap between PC1 and PC2 is completely 
closed (Fig. 1b).  In vitro cross-linking coupled with mass spectrometry suggested that sub-
domain PN2 of CusA should interact with the N-terminus of the CusB membrane fusion 
protein.
22
  This result agrees with the cross-linking experimentwhere the N and C-termini of 
AcrA was found to contact PN2 and PC1 of AcrB.
19
  Thus, sub-domains PN2 and PC1 of 
CusA most likely form the binding surface for the membrane fusion protein CusB. 
Perhaps the most interesting secondary structural feature appears in the cleft region of 
the periplasmic domain.  Residues located on the left side of the wall (Fig. 2), formed by one 
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-helix (residues 690-706) and three -sheets (residues 681-687, 711-716 and 821-827), 
appear to tilt into the cleft to close the opening.  Surprisingly, residues 665-675, located at 
the bottom of the cleft, form an -helix.  This structural feature, not found in AcrB and 
MexB, likely governs the specificity of the CusA pump.  The -helix orients horizontally and 
roughly divides the transmembrane and periplasmic domains into two compartments.  
Located just above this horizontal helix, we find three proximal methionine residues, M573, 
M623 and M672, presumably creating a three-methionine specific binding site for Cu(I) and 
Ag(I) ions.
23,24
  Notably M672 is also one of the residues within the horizontal helix.  Site-
directed mutagenesis had suggested that these three methionine residues are essential for 
mediating copper resistance.
4
  Indeed, a strong peak at the copper edge was observed at the 
center of these three methionines in our CusA-Cu(I) crystal derivative, indicating the binding 
of a Cu(I) ion in a three-sulfur binding site (see below).  The location of this Cu(I) binding 
site is coincident with the multidrug binding site in AcrB at the periplasmic cleft.
25,26
  
Intriguingly, the overall structure of the CusA-Cu(I) complex is quite distinct from 
that of apo-CusA (Fig. 2).  Superimposition of these two structures gives an overall RMSD 
of 3.9 Å (for 1,006 C

 atoms).  As mentioned above, the bound Cu(I) ion was found to 
coordinate residues M573, M623 and M672.  These three methionines specifically form a 
typical three-methionine coordination site for binding Cu(I)/Ag(I).
23,24
  The signal for this 
bound copper is strong with a large peak height of 44 .  Binding of Cu(I) initiates 
significant conformational changes in the periplasmic as well as transmembrane domains of 
CusA.  Perhaps, the most noticeable difference between the apo and ion-bound structures 
appears in the PC2 region (Fig. 2 and Fig. S3).  Cu(I) binding leads to a 30
o
 swing of the 
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entire PC2 sub-domain.  This motion shifts PC2 away from the PC1 sub-domain.  The hinge 
for this rotational movement appears to be at the junction between sub-domains PC2 and DC 
with residues G721 and P810 forming the hinge.  As a consequence, the gap between PC1 
and PC2 appears to open up after binding this metal ion.  This gap presumably creates an 
entrance for metal ions from the periplasmic space.  The horizontal helix, residues 665-675, 
located inside the cleft also makes a substantial movement.  The C-terminal end of this helix 
is found to tilt upward by 21
o
 in the Cu(I)-bound structure with respect to the apo form (Fig. 
2c).  This tilting motion allows M672 to move closer to M573 and M623 to complete the 
three-methionine coordination site.  Coupled with this movement, TM8 also shifts in position 
to a more vertical orientation while retaining its -helical structure.  Overall, the N-terminal 
end of TM8 is found to shift away from the core by 10 Å after Cu(I) binding. 
For the CusA-Ag(I) complex, an anomalous difference Fourier peak (38 ) was found 
at the center of residues M573, M623 and M672, indicating that the bound Ag
+
 ion is 
coordinated by these three methionines (Fig. 2d).  The overall conformational changes 
triggered by Cu(I) and by Ag(I) binding are nearly identical.  Superimposition of the CusA-
Cu(I) and CusA-Ag(I) structures gives an overall RMSD of 1.0 Å (for 1,021 C

s).  Based on 
the crystal structures, the horizontal helix in the cleft directly interacts with the N-terminal 
end of TM8.  The movement of TM8 may relate directly to transmembrane signaling and 
could initiate the translocation of a proton across the membrane.  Indeed, in the AcrB pump, 
there is evidence that proton translocation is coupled to the conformational change in 
TM8.
12,27
  The change in conformation takes place in TM8 by reeling in some random coil 
12
  In addition, when individual residues of the proton-relay 
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network was changed to alanine, disrupting the hydrogen bonds in the system, it was reported 
that TM8 of AcrB becomes longer and extends into the periplasmic domain.
27
  In contrast to 
AcrB, the helical structure of the N-terminus of TM8 in CusA is retained after metal binding.  
Instead, the N-terminal end of TM8 moves outward, together with the movement of the PC2 
sub-domain.  According to the crystal structures of the apo and bound-CusA, we confirm 
prior speculation that the structure of apo-AcrB is actually the detergent-bound form.
13 
Intriguingly, it appears that the binding of Cu(I) or Ag(I) also triggers significant 
conformational changes in the other transmembrane helices of  the pump.  In addition to the 
movement of TM8, all other transmembrane helices except TM2 shift horizontally by as 
much as 4 Å, mimicking the motion of TM8.  Further, TM1, TM3 and TM6 readjust in an 
approximately 3 Å upward shift with respect to the inner membrane surface.  The net result is 
that all three of these transmembrane helices move towards the periplasm by one turn.  
Mutagenesis studies of the transmembrane domain of CusA indicated the conserved charged 
residue D405 of TM4 to be essential for transporter function.
4
  Based on the crystal structure, 
this acidic residue interacts with E939 and K984 (Fig. S4).  It is possible that these three 
charged residues participate in forming the proton-relay network in the transmembrane 
region of the pump.  
Coupled with the above conformational changes, the sub-domain PN1 at the 
periplasmic domain was also found to undergo substantial movement.  Overall, PN1 also 
shifts upward by 3 Å.  This moves the central pore helix upward by one turn upon metal 
binding.  It should be noted that the binding of metal ions does not significantly affect the 
conformation of the sub-domains DN, DC, PN2 or the transmembrane helix TM2.  PN2 has 
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been found to interact with the N-terminus of the CusB membrane fusion protein.  Thus, we 
expect that PN2 and TM2 could move in the presence of CusB, to accommodate the binding 
of this membrane fusion protein.  If TM8 were responsible for signaling the binding of metal 
ions, it would suggest that TM2 is important for detecting the presence of the membrane 
fusion component CusB. 
 Flexible docking was then carried out, where flexibility between the domains of 
CusB was accounted for by docking Domains 1 and 2 of CusB separately to the structure of 
apo-CusA using 3-D dock,
28
 followed by energy minimization with the CHARMM27 force 
field
29
 and steered molecular dynamics to restrain CusB to fit the docked fragments.  The 
resulting CusBA structure suggests that Domains 1 and 2 of the CusB membrane fusion 
protein contact CusA at the interface between PN2 and PC1 (Fig. S5).   
The full-length CusA includes 34 methionine residues with 18 of them located in the 
transmembrane domain.  Of the 18 methionines, six are paired up to form three distinct 
methionine pairs (Fig. S1b).  These methionine pairs are M410 of TM4 and M501 of TM6; 
M403 of TM4 and M486 of TM6; and M391 of TM4 and M1009 of TM12 (Fig. 3, Fig. S6 
and Fig. S7).  Copper tolerance proteins, such as CusF,
30,31
 CueR
32
 and Atx1,
33
 have been 
found to utilize two-methionine or two-cysteine binding pockets to carry their Cu(I)/Ag(I) 
cargos.  Thus, these methionine pairs could potentially form binding sites for Ag(I) and Cu(I) 
in the transmembrane region of the pump.  If this is the case, then CusA could transport these 
metal ions from the cytoplasm along these methionine pairs.  In the periplasmic domain of 
CusA, we have also found two pairs of methionines (M271-M755, and M738-M792) in 
addition to the three-methionine metal binding site (Fig. 3).  In view of the crystal structures, 
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these six methionine pairs/clusters are deemed to be important for binding and transport of 
metal ions. 
We then determined whether the CusA protomer forms a channel by using the 
program CAVER (http://loschmidt.chemi.muni.cz/caver) and found that each protomer of 
CusA forms a channel spanning the entire transmembrane region up to the bottom of the 
periplasmic funnel (Fig. S8).  Intriguingly, the channel includes four methionine pairs, three 
(M410-M501, M403-M486, M391-M1009) from the transmembrane region and one (M271-
M755) from the periplasmic domain, as well as the three-methionine binding site formed by 
M573, M623 and M672 (Fig. 3).  Taken together these five methionine pairs/clusters are 
likely to form a relay network facilitating metal ion transport.  Remarkably, this channel 
spans almost the entire length of each protomer, from the transmembrane domain through to 
the bottom of the periplasmic funnel region, and is likely to represent a real path for 
transporting the metal ion from both the cytoplasm and periplasm to the periplasmic funnel 
for extrusion.  It should be noted that the pair M738-M792, located at the top of the funnel, is 
not located directly within this channel. 
We made an E. coli knock-out strain BL21(DE3)∆cueO∆cusA that lacks both the 
cueO and cusA genes.  We mutated M573, M623 and M672, which are members of the 
binding site triad inside the cleft of the periplasmic domain, into isoleucines (M573I, M623I 
and M672I).  We then expressed these three mutant transporters in BL21(DE3)∆cueO∆cusA, 
and tested their ability to confer copper and silver resistance in vivo.  We found that the CusA 
mutants, M573I, M623I and M672I are unable to relieve the copper or silver sensitivity of 
strain BL21(DE3)∆cueO∆cusA (Tables S3 and S4), thus agreeing well with the work of 
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Franke et al.
4
 in which M573, M623 and M672 were shown to be essential for the function of 
CusA. 
We mutated M410 into an isoleucine (M410I) to disrupt the pair formed by M410 and 
M501 at the bottom of the transmembrane and also replaced M486 and M391, which pair 
with M403 and M1009, with isoleucines (M486I and M391I).  Expression of these three 
mutants in BL21(DE3)∆cueO∆cusA showed a significant decrease in the level of copper and 
silver tolerances when compared with cells expressing wild-type CusA. In addition, we 
introduced M755I in the periplasmic domain.  Again, when expressed in 
BL21(DE3)∆cueO∆cusA, this mutant transporter (M755I) showed a decrease in copper/silver 
tolerance in comparison with cells harboring the wild-type transporter.  We then made two 
mutant transporters, M738I and M792I, in which these two methionines form a pair at the top 
of the periplasmic funnel.  Unlike the other mutations, cells expressing these mutant 
transporters do not elevate the sensitivity level for copper or silver compared with cells 
expressing the wild-type pump (Tables S3 and S4).  Together, these results strongly support 
five of these methionine pairs/clusters engaging in the methionine-residue ion relay channel. 
Based on the crystal structure of CusA, it is expected that the charged residues D405, 
E939 and K984 are important for the proton-relay network of the pump, and these in turn 
were replaced with alanines (D405A, E939A and K984A) to disrupt the hydrogen-bonded 
network.  Indeed, cells expressing this mutant were unable to tolerate copper and silver, 
demonstrating that these three charged residues are essential for the transporter‟s functioning.   
To investigate whether CusA can transport metal ions from the cytoplasm, we 
reconstituted the purified CusA protein into liposomes containing the fluorescent indicator 
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Phen Green SK (PGSK) in the intravesicular space (Fig. S9).  The intravesicular and 
extravesicular pHs of these proteoliposomes were 6.6 and 7.0, respectively.  We then 
determined whether these proteoliposomes can capture metal ions from the extravesicular 
medium with a stopped-flow transport assay.  (The charged metal ions are unlikely to diffuse 
spontaneously across membrane bilayers.)  When Ag
+
 ions were added into the 
extravesicular medium, we detected the quenching of the fluorescence signal, suggesting the 
uptake of Ag
+
 into the intravesicular space (Fig. 4a).  The uptake into proteoliposomes is 
presumably due to the CusA active transport activity.  It should be noted that no decrease in 
fluorescence signal was detected in the absence of a pH gradient (i.e. no differential pH) 
between the inside and outside of the proteoliposomes, or if the intravesicular pH is higher 
than the extravesicular pH (i.e. reverse pH gradient) (Fig. S10).     
In addition to the above experiment, we investigated the methionine residues that 
were shown to be important for copper and silver tolerances with the above transport assay.  
We expressed, purified and reconstituted the CusA mutants, M573I, M623I and M672I, into 
liposomes encapsulated with the same fluorescence indicator.  Surprisingly, these mutant 
transporters do not take up Ag
+
 from the extravesicular medium of the proteoliposomes (Fig. 
4a).  It is clear that even single point mutations M573I, M623I or M672I abolish the process 
of metal transport across the membrane.  Thus, it is expected that this three-methionine site is 
requisite for both metal binding and export.   
We then purified the mutants, M391I, M486I and M755I, and reconstituted them into 
liposomes.  In these three cases, the fluorescence signals did not attenuate as indicated by the 
stopped-flow assay (Fig. 4a).  When compared with the result from the wild-type CusA, this 
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suggests that the M391I, M486I and M755I mutant transporters are unable to actively 
transport Ag
+
 across the membrane. 
Although all of the above experimental results strongly suggest that these five 
methionine pairs/clusters (Fig. 3) are important for metal transport, we cannot definitively 
rule out the possibility that these mutations may affect the structure of the pump and in that 
way impair metal binding.  Nonetheless, our collective experiments provide direct 
compelling evidence that CusA is capable of taking up Ag
+
 from the cytoplasm. 
The crystal structure of CusA suggests that the charged residues D405, E939 and 
K984 in the transmembrane domain may be important for proton translocation.  When 
reconstituted into liposomes, mutant transporters (D405A, E939A and K984A) do not take 
up Ag
+
 into the intravesicular space (Fig. 4b), thus confirming the importance of D405, E939 
and K984 for the function of the pump. 
It is likely that CusA operates through an alternating-access mechanism.
10-12
 Thus we 
superimposed a protomer of apo-CusA onto each protomer of the “asymmetric” AcrB (pdb 
code: 2DHH).
10
 Likewise, we also superimposed a protomer of CusA-Cu(I) onto those of the 
AcrB pump.  These superpositions gave high overall RMSDs, each RMSD exceeding 11 Å.  
However, when the portion of the apo-CusA protomer that contains only sub-domains PC1, 
PC2, PN1 and PN2 was supimposed onto those of the “extrusion”, “binding” and “access” 
conformers of AcrB (2DHH),
10
 we obtained much smaller RMSDs of 4.7 Å, 5.6 Å and 5.5 Å.  
Similarly, superpositions of the periplasmic domain (only containing PC1, PC2, PN1 and 
PN2) of a protomer of CusA-Cu(I) onto those of the “extrusion”, “binding” and “access” 
conformers of AcrB (2DHH)
10
 gave RMSDs of 6.2 Å, 5.0 Å and 5.3 Å, respectively.  These 
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superpositions suggest that the conformation of the apo-CusA protomer may correspond to 
the “extrusion” state, and that the CusA-Cu(I) protomer structure may represent the “binding” 
conformation of the pump.  If this is the case, CusA may go through a cyclic conformational 
change, from the “access”, through to the “binding” and finally to the “extrusion” conformer, 
as suggested for the AcrB pump,
10-12
 to export copper/silver. 
We also calculated the dynamics of the trimeric CusA pump using the elastic network 
model.
34
  The result indeed suggests that CusA functions through three coupled motions in 
which the periplasmic cleft formed by sub-domains PC1 and PC2, presumably acting as the 
periplasmic metal entry site, alternately open and close (Figs. S11 and S12). 
There is strong evidence that the CusCBA system captures Cu(I) and Ag(I) ions from 
the periplasm.  The periplasmic membrane fusion protein CusB is known to specifically bind 
Cu(I).
35
  It has also been demonstrated that the periplasmic chaperone protein CusF can 
directly transfer these metals to CusB.
36
  Indeed, the crystal structure of CusB indicates that 
this membrane fusion protein consists of multiple Cu(I) and Ag(I) binding sites.
22
  Thus, in 
addition to capturing metal ions from the periplasm, the CusA pump may also be able to take 
up these metals from the cytoplasm.  In fact, it has been demonstrated that the divalent cation 
efflux pump CzcA is capable of catalyzing the transport of divalent cations, such as Zn
2+
, 
from the cytosol.
37
 Further, the AcrD multidrug efflux pump has also been observed to 
capture aminoglycosides from both the periplasm and cytoplasm.
38
  
We hypothesize that CusA can pick up metal ions from both the cytoplasm and 
periplasm.  We propose that this transporter utilizes methionine pairs/clusters to export Cu(I) 
and Ag(I).  The periplasmic cleft of CusA presumably remains closed when there is no 
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Cu(I)/Ag(I).  In the presence of Cu(I) or Ag(I) ions, the periplasmic cleft opens.  Metal ions 
could enter the three-methionine binding site inside the cleft directly through the periplasmic 
cleft or via the methionine pairs within the transmembrane region (Fig. 3).  Thus, transport of 
a metal ion within the membrane is likely to involve a stepwise process that shuttles the 
metal ion from one methionine pair to another along the pathway.  The locations of these 
methionine pairs/clusters allow us to depict a direct pathway for metal transport and 
extrusion.  The metal ion bound at the three-methionine binding site of the periplasmic cleft 
could then be released to the nearest methionine pair, formed by M277 and M755, following 
which the metal ion could then be released into the central funnel to reach the CusC channel 
for final extrusion.  Interestingly, the proposed metal export pathway in the periplasmic 
domain, based on the location of the methionine pairs/clusters, is similar to the proposed drug 
export pathway in AcrB.
12
 Nonetheless, our mechanism for export of metal ions 
intermediated by binding to sequential methionine pairs/clusters is fully consistent with the 
body of evidence in all of the structural and mutagenesis studies reported here. 
 
Methods Summary 
Crystals were grown by sitting-drop vapor diffusion.  Phasing, refinement methods 
and statistics are provided in the Methods. 
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Figures and Captions 
 
 
 
 
 
Fig. 1.  Structure of the CusA efflux pump.  (a) Ribbon diagram of the CusA homotrimer 
viewed in the membrane plane.  Each subunit of CusA is labeled with a different color.  Sub-
domains DN, DC, PN2, PC1 and PC2 are labeled on the front protomer (green).  The location 
of PN1 in this protomer is behind PN2, PC1 and PC2 (see text).  (b) Top view of the CusA 
trimer.  The six sub-domains are labeled yellow (DN), blue (DC), pink (PN1), orange (PN2), 
green (PC1) and red (PC2).  In the apo-CusA structure, the cleft between PC1 and PC2 is 
closed.  
1a 1b 
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Fig. 2.  Comparison of the apo and metal bound structures of CusA.  (a) Superposition of a 
monomer of apo-CusA (red) onto a monomer of Cu(I) bound-CusA (green).  The bound Cu(I) 
is pink.  The arrow represents a major swing of the PC2 sub-domain initiated by Cu(I) 
binding.  (b) Conformational changes of the periplasmic domain of CusA.  The conformation 
of each sub-domain of CusA before (left) and after (right) Cu(I) binding.  The periplasmic 
cleft formed between PC1 and PC2 is opened after Cu(I) binding.  The bound coppers in the 
CusA-Cu(I) structure are blue.  M573, M623 and M672 forming a metal binding site at the 
periplasmic cleft are shown in stick form (yellow).  (c) The changes in conformation of the 
horizontal helix and TM8, are shown in a superimposition of the structures of apo (red) and 
Cu(I)-bound (green) CusA.  The bound Cu(I) is shown as a pink sphere.  Anomalous map of 
the bound Cu(I), contoured at 8, is in blue.  M573, M623 and M672 are shown as sticks.  (d) 
The Ag(I) binding site.  The bound Ag(I) is shown as a gray sphere.  Anomalous map of the 
bound Ag(I) , contoured at 10, is in red.  
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Fig. 3.  Proposed metal transport pathway of the CusA efflux pump.  (a) The five methionine 
pairs/clusters of the apo-CusA transporter form a pathway for metal export.  These five 
methionines are shown as spheres (C, green; O, red; N, blue; S, orange).  The carbon atoms 
3a 
3b 
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of the pair M738-M792, located at the top of the periplasmic funnel, are in blue.  This pair 
does not engage directly in the methionine-residue relay network.  (b) The five methionine 
pairs/clusters of the Cu(I) bound-CusA transporter form a pathway for metal export.  These 
five methionines are given as spheres (C, pink; O, red; N, blue; S, orange).  The carbon 
atoms of the pair M738-M792, located at the top of the periplasmic funnel, are in orange.  
This pair is not involved in the methionine-residue relay network.  The pair M271-M755 is 
located at the bottom of the periplasmic funnel where the metal ion could then be released for 
final extrusion.  The paths for metal transport through the periplasmic cleft and 
transmembrane region are illustrated with black curves. 
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Fig. 4.  Stopped-flow transport assay of reconstituted CusA with extravesicular Ag
+
 ion.  (a) 
Mutants of the methionine-residue relay network.  The decrease in fluorescence signal of 
4a 
4b 
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PGSK mediated by proteoliposomes of wild-type CusA indicates the transport of Ag
+
 across 
the membrane.  The stopped-flow traces are the cumulative average of four successive 
recordings (wild-type CusA, black curve; M486I mutant, green curve; M391I mutant, brown 
curve; M573I mutant, red curve; M623I, purple curve; M672I, orange curve; M755I, cyan 
curve; control liposome, dark blue curve).  (b) Mutants of the proton relay network.  The 
stopped-flow traces are the cumulative average of four successive recordings (D405A mutant, 
dark blue curve; E939A mutant, red curve; K984A mutant, green curve).  The wild-type 
CusA and control liposomes are shown in part (a).  
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Supplemental Materials 
Methods 
Cloning, expression and purification of CusA 
Briefly, the full-length CusA membrane protein containing a 6xHis tag at the N-
terminus was overproduced in E. coli BL21(DE3)acrB cells, which harbors a deletion in the 
chromosomal acrB gene,  possessing pET15bcusA.  Cells were grown in 12 L of LB 
medium with 100 g/ml ampicillin at 37oC.  When the OD600 reached 0.5, the culture was 
treated with 1 mM IPTG to induce cusA expression, and cells were harvested within 3 h.  The 
collected bacteria were resuspended in low salt buffer containing 100 mM sodium phosphate 
(pH 7.2), 10 % glycerol, 1 mM ethylenediaminetetraacetic acid (EDTA) and 1 mM 
phenylmethanesulfonyl fluoride (PMSF), and then disrupted with a French pressure cell.  The 
membrane fraction was collected and washed twice with high salt buffer containing 20 mM 
sodium phosphate (pH 7.2), 2 M KCl, 10 % glycerol, 1 mM EDTA and 1 mM PMSF, and 
once with 20 mM HEPES-NaOH buffer (pH 7.5) containing 1 mM PMSF.  The membrane 
protein was then solubilized in 1 % (w/v) Cymal-6.  Insoluble material was removed by 
ultracentrifugation at 100,000 x g.  The extracted protein was purified with a Ni
2+
-affinity 
column.  The purity of the CusA protein (>95%) was judged using 10% SDS-PAGE stained 
with Coomassie Brilliant Blue.  The purified protein was then dialyzed and concentrated to 
20 mg/ml in a buffer containing 20 mM Na-HEPES (pH 7.5) and 0.05% CYMAL-6. 
For 6xHis SeMet-CusA protein expression, a 10 ml LB broth overnight culture 
containing E. coli BL21(DE3)acrB/pET15bcusA cells was transferred into 120 ml of LB 
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broth containing 100 g/ml ampicillin and grown at 37oC.  When the OD600 value reached 
1.2, cells were harvested by centrifugation at 6000 rev/min for 10 min, and then washed two 
times with 20 ml of M9 minimal salts solution.  The cells were re-suspended in 120 ml of M9 
media and then transferred into a 12 L pre-warmed M9 solution containing 100 µg/ml 
ampicillin.  The cell culture was incubated at 37
o
C with shaking. When the OD600 reached 
0.4, 100 mg/l of lysine, phenylalanine and threonine, 50 mg/l isoleucine, leucine and valine, 
and 60 mg/l of L-selenomethionine were added. The culture was induced with 1 mM 
isopropyl--D-thiogalactopyranoside (IPTG) after 15 min.  Cells were then harvested within 
3 h after induction.  The procedures for purifying the 6xHis SeMet-CusA were identical to 
those of the native protein. 
 
Crystallization of CusA 
Crystals of the 6xHis CusA were obtained using sitting-drop vapor diffusion.  The 
CusA crystals were grown at room temperature in 24-well plates with the following 
procedures.  A 2 l protein solution containing 20 mg/ml CusA protein in 20 mM Na-HEPES 
(pH 7.5) and 0.05% (w/v) CYMAL-6 was mixed with a 2 l of reservoir solution containing 
10% PEG 3350, 0.1 M Na-MES (pH 6.5), 0.4 M (NH4)2SO4, 1% JM 600 and 10% glycerol.  
The resultant mixture was equilibrated against 500 l of the reservoir solution.  The 
crystallization conditions for SeMet-CusA were the same as those for the native CusA 
protein.  Crystals of CusA grew to a full size in the drops within a month.  Typically, the 
dimensions of the crystals were 0.2 mm x 0.2 mm x 0.2 mm.  Cryoprotection was achieved 
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by raising the glycerol concentration stepwise to 30% with a 5% increment in each step.  
Crystals of the gold or tantalum derivatives were prepared by incubating the crystals of apo-
CusA in solution containing 10% PEG 3350, 0.1 M Na-MES (pH 6.5), 0.4 M (NH4)2SO4, 1% 
JM 600, 10% glycerol, 0.05% (w/v) CYMAL-6, and 1 mM KAuCl4 or 5 mM Ta6Br12
.
2Br for 
1.5 hours at 25
o
C. 
The CusA-Cu(I) complex crystals were prepared by incubating crystals of apo-CusA 
in solution containing 10% PEG 3350, 0.1 M Na-MES (pH 6.5), 0.4 M (NH4)2SO4, 1% JM 
600, 10% glycerol, 2 mM [Cu(CH3CN)4]PF6, 2 mM tris(2-carboxyethyl)phosphine (TCEP) 
and 0.05% (w/v) CYMAL-6 for 1 hour at 25
o
C.  Crystals of the CusA-Ag(I) complex were 
prepared using a similar method in solution containing 10% PEG 3350, 0.1 M Na-MES (pH 
6.5), 0.4 M (NH4)2SO4, 10% glycerol, 1 mM AgNO3 and 0.05% (w/v) CYMAL-6 for 1 hour 
at 25
o
C. 
 
Data collection, structural determination and refinement  
All diffraction data were collected at 100K at beamline 24ID-C located at the 
Advanced Photon Source, using an ADSC Quantum 315 CCD-based detector.  Diffraction 
data were processed using DENZO and scaled using SCALEPACK.
39
  The crystals belong to 
space group R32 (Tables S1 and S2).  Based on the molecular weight of CusA (115.72 kDa), 
a single molecule per asymmetric unit with a solvent content of 67.5% is expected.  Two 
heavy-atom derivatives (gold and Ta6Br12 cluster) and the selenomethionyl-substituted 
(SeMet) crystal were isomorphous with the native crystal (Table S1).  Ten heavy-atom sites 
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for the gold derivative were identified using SHELXC and SHELXD
40
 as implemented in the 
HKL2MAP package.
41
  These heavy-atom sites were refined using the program 
MLPHARE.
42,43
  The resulting phases were subjected to density modification by 
RESOLVE
44
 using the native structure factor amplitudes.  Density modified phases were 
good enough to allow us to visualize the secondary structural features of the molecule.  These 
phases were then used to locate three Ta6 clusters and 31 selenium sites using the 
corresponding data sets.  The final experimental phases were generated using 10 Au, three 
Ta6 and 33 Se sites.  The Ta6 sites were treated as super-atoms containing all six tantalum 
atoms at a given site.  These phases were then subjected to density modification and phase 
extension to 3.52 Å-resolution using the program RESOLVE.
44
  The resulting phases were of 
excellent quality that enabled tracing of most of the molecule.  The full-length CusA protein 
consists of 34 methionine residues.  The SeMet data not only augmented the experimental 
phases, but also helped in tracing the molecules by anomalous difference Fourier maps where 
we could ascertain the proper registry of SeMet residues.  After tracing the initial model 
manually using the program Coot,
45
 the model was refined against the native data at 3.52 Å-
resolution using TLS refinement techniques adopting a single TLS body as implemented in 
PHENIX
46
 leaving 5% of reflections in Free-R set.  Iterations of refinement using PHENIX
46
 
and CNS
47
 and model building in Coot
45
 lead to the current model, which consists of 1,025 
residues with excellent geometrical characteristics (Table S1). 
While the structure of CusA-Cu(I) complex could be determined using molecular 
replacement, the structure resulted in a relatively high refinement R-factor of 48.7%.  Upon 
inspection of the electron density maps, it was found that several regions, especially the PC2 
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sub-domain, of CusA-Cu(I) have undergone significant conformational changes as discussed 
in the main text.  To aid modeling of these conformational changes in the least biased manner, 
SAD phasing using the program PHASER
48
 was employed to obtain experimental phases in 
addition to the phases from the structural model of apo-CusA that has sub-domains PC2 and 
PN1 removed.  Phases were then improved using RESOLVE.
44
  Even though the data 
resolution is low (4.10 Å), the phases were of sufficient quality that allowed for modeling of 
the conformational change (Fig. S3) using the program COOT.
45
  At a later stage, higher 
resolution (3.88 Å) data of the CusA-Cu(I) were collected (Table S2).  To reduce radiation 
damage, the data was collected away from the copper absorption edge, at 1.033 Å, where Cu 
still has ~2.4 anomalous electrons.  The model was refined using PHENIX
46
 and CNS.
47
  
Since the X-ray absorption edge of Ag was not reachable at the synchrotron beamline 
(L-edges below 4 KeV and K-edge above 25 KeV), the data were collected at the copper 
edge where Ag has an anomalous contribution of ~3.5e
-
.  The structure of the CusA-Ag(I) 
complex was phased using molecular replacement by using CusA-Cu(I) as the search model.  
Structural refinement was then performed using PHENIX
46
 and CNS
47
 by refining the model 
against the 4.35 Å-resolution data from the CusA-Ag(I) crystal (Table S2). 
 
Docking structures of CusB onto CusA 
Initial rigid-body docking of the crystal structures of CusA and CusB did not reveal 
any feasible complexes that satisfied the CusA-K150/CusB-K95 crosslinking constraint,
22
 
indicating that docking may likely require a conformational change in one or both molecules.  
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As previously mentioned in this paper it has been hypothesized that the PN2 and PC1 sub-
domains may move to accommodate CusB.  For CusA, the normal modes from the 
Anisotropic-Network-Models (ANMs)
34
 were calculated, but did not reveal any appropriate 
structures.  For CusB, ANM revealed significant hinge motions between Domains 1 and 2.  
And, following this lead these two domains were docked individually onto CusA.  Steered 
molecular dynamics simulations were then used to drive the CusB into a docked form 
agreeing with the individually docked fragments, thus allowing for the flexibility of the PC1, 
PN2 and TM2 domains of CusA. 
 
Data-driven docking of Domains 1 and 2 of CusB 
Rigid-body docking was performed using the 3D-dock software suite,
28
 which utilizes 
the Katchalski-Katzir algorithm.
49
  For all runs, 10,000 conformations were generated and 
filtered using the following data-driven constraints: transmembrane helices were masked 
from docking interactions; and side-chain amines of CusA-K150 and CusB-K95 were within 
25 Å
22
; CusB was oriented so that its domains were free to interact with CusC and its N-
terminus was directed towards the inner membrane. 
 
Steered Molecular Dynamics and Energy minimization 
An initial conformation was calculated by aligning CusB with the two individually 
docked fragments.  To relax CusB from this conformation, we utilized steered molecular 
dynamics to guide the center of mass of domains 1 and 2 into the corresponding docked 
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position.  Energy minimization was employed to alleviate steric clashes.  During the 
simulation CusA was kept rigid with the exception of TM2, PN2, and PC1, which make up 
most of the CusB binding region.  All calculations were performed using NAMD
50
 and the 
CHARMM27 force field.
29 
 
Double knocked-out strain and susceptibility assays 
The double knocked-out E. coli strain BL21(DE3)∆cueO∆cusA was produced from 
the BL21(DE3) strain using an RED disruption system as described by Datsenko and 
Wanner.
51
  The ∆cueO::kan cassette, which was used to replace the chromosomal cueO gene, 
was produced by PCR, and then introduced into pKD46/BL21(DE3) by electroporation.  The 
knocked-out BL21(DE3)∆cueO::kan strain was selected on LB plate containing 30 μg/ml 
kanamycin, and verified by PCR.  The kanamycin resistant gene was then released to 
generate the BL21(DE3)∆cueO knocked-out strain.  The deletion of cusA from 
BL21(DE3)∆cueO was done using similar procedures as described above to generate the 
final BL21(DE3)∆cueO∆cusA double knocked-out strain.   
The susceptibility to copper of E. coli BL21(DE3)∆cueO∆cusA harboring 
pET15bcusA expressing the wild-type or mutant transporters, or the pET15b empty vector 
was tested on agar plates.  Cells were grown in Luria Broth (LB) medium with 100 g/ml 
ampicillin at 37 
o
C.  When the OD600 reached 0.5, the cultures were induced with 0.5 mM 
IPTG and harvested in two hours after induction.  The minimum growth inhibitory 
concentrations (MICs) to copper of E. coli BL21(DE3)∆cueO∆cusA (incoculum, 500 cells/ml) 
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harboring these vectors were then determined using LB agar containing 50 g/ml ampicillin, 
0.1 mM IPTG and different concentrations of CuSO4 (0.25 to 2.75 mM in steps of 0.25 mM).   
For the susceptibility to silver of E. coli BL21(DE3)∆cueO∆cusA harboring these 
vectors, cells were grown in Mueller Hinton (MH) medium containing 100 g/ml ampicillin 
with the same procedures.  The MICs to silver of E. coli BL21(DE3)∆cueO∆cusA 
(incoculum, 500 cells/ml) harboring these vectors were then performed in MH agar 
containing 50 g/ml ampicillin, 0.1 mM IPTG and different concentrations of AgNO3 (5.0 to 
50.0 M in steps of 2.5 M).  The expression level of each mutant in 
BL21(DE3)∆cueO∆cusA is similar to that of the wild-type transporter as indicated by 
Western blot analysis (Fig. S13).  Bacterial growth in the LB or MH agar was recorded after 
24 h of incubation at 37
o
C.  Each assay was repeated at least four times to ensure the 
reproducibility of the results. 
 
Reconstitution and stop-flow transport assay 
The purified wild-type CusA, M391I, M486I, M573I, M623I, M672I, M722I, D405A, 
E939A or K984A was reconstituted into liposomes made of E. coli polar lipid and egg-yolk 
phosphatidylcholine (Avanti Polar Lipids) in a molar ratio of 3:1.  Briefly, 50 g of the 
purified protein (wild-type CusA or its mutant) was added to 4.5 mg of lipids dispersed in the 
reconstitution buffer containing 20 mM HEPES-KOH, pH 6.6.  The protein samples were 
completely incorporated into liposomes as judged using 10% SDS-PAGE stained with 
Coomassie Brilliant Blue.  Control liposomes were prepared following the same procedure 
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without adding protein.  200 M fluorescence indicator Phen Green SK (PGSK) (Invitrogen) 
was encapsulated by two freeze-thaw cycles, followed by gel filtration to remove the 
untrapped dye.  Transport experiments were performed at 25
o
C on a stopped-flow apparatus 
(Hi-Tech Scientific) connected to a spectrofluorometer (PerkinElmer LS55).  
Proteoliposomes and a transport assay buffer (20 mM HEPES-KOH pH 7.0 and 1 mM 
AgNO3) were loaded into a two separate syringes of equal volume.  Transport reactions were 
initiated by pushing 400 l fresh reactants at a 1:1 ratio through the 90 l mixing cell at a 
flow rate of 2 ml/s. Stopped-flow traces were the cumulative average of four successive 
recordings at 530 nm with the excitation wavelength at 480 nm. 
 
Dynamics Simulations 
The observed conformational changes between the Cu(I) bound and the apo forms, 
displayed in Fig. 2, are shown to be intrinsically favored by the new structure through the use 
of normal mode analysis (Fig. S11).  A coarse-grained elastic network model
34
 was 
investigated that is composed of the C
α
 atom coordinates and a portion of coarse-grained 
lipid bilayer between the trans-membrane domains.  The opening and closing of the space 
between PC1 and PC2 coupled with a shift of TM8 is reproduced by this simple model (Fig. 
S12).  The model does not show simultaneous opening and closing of all three periplasmic 
heavy metal entrance sites, but rather has a more complex opening/closing motion in which 
each pair of two adjacent is alternately open and closed.  All three combinations of these 
coupled motions are obtained by using just two low energy motions. 
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Supplemental Tables 
Table S1. Data collection, phasing and structural refinement statistics of apo-CusA. 
  
Native 
CusA 
Derivatives 
  Au(III) Ta6Br12
2+ 
Se (peak) 
Data Collection         
Detector type/source 
ADSQ 
Q315 
ADSQ 
Q315 
ADSQ 
Q315 
ADSQ 
Q315 
 APS-24IDC APS-24IDC APS-24IDC APS-24IDC 
Wavelength (Å) 0.9791 1.0398 1.0089 0.9791 
Space group R32 R32 R32 R32 
Cell constants (Å) 
a = b = 
178.42, c = 
285.75 
a = b = 
179.31, c = 
287.10 
a = b = 
178.34, c = 
284.23 
a = b = 
178.21, c = 
285.57 
Resolution (Å) 
50-3.52 
(3.67-3.52) 
50-4.31 
(4.50-4.31) 
50-3.52 
(3.66-3.52) 
50-3.68 
(3.81-3.68) 
Total reflections 432,346 759,214 604,127 509,675 
Unique reflections 21,820 14,948 24,417 19,264 
Redundancy 6.9 (6.9) 3.2 (2.8) 3.8 (3.9) 3.9 (3.9) 
Completeness (%) 94.2 (95.8) 100 (100) 99.9 (100) 100 (100) 
Rsym(%) 5.7 (43.5) 10.2 (35.9) 6.2 (37.7) 7.5 (46.9) 
Average I/(I) 32.5 (4.0) 17.3 (5.3) 21.7 (3.4) 19.7 (2.6) 
MIR Phasing         
Number of sites  10 3 33 
Phasing power 
(acentric/centric)  1.51/1.10 1.09/1.23 2.51/1.51 
Rcullis (acentric/centric)  0.58/0.80 0.76/0.71 0.84/1.23 
Figure of merit 
(acentric/centric)   0.29/0.36  
Refinement CusA       
Resolution (Å) 50-3.52    
Rwork (%) 23.8    
Rfree (%) 27.5    
Protein residues built 1,025    
Protein atoms  7,884    
rms deviation from ideal     
      Bond lengths (Å) 0.004    
      Bond angles (°) 0.874    
Ramachandran          
 most favored  87.6    
 additional allowed  11.4    
 generously allowed 1.0    
 disallowed  0.0       
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Table S2. Data collection, phasing and structural refinement statistics of the CusA-Cu(I) and 
CusA-Ag(I) complexes. 
 Cu(I) (peak) Cu(I) Ag(I) 
Data Collection    
Detector type/source ADSQ Q315 ADSQ Q315 ADSQ Q315 
 APS-24IDC APS-24IDC APS-24IDC 
Wavelength (Å) 1.3779 1.0333 1.3779 
Space group R32 R32 R32 
Cell constants (Å) 
a = b = 
178.21, c = 
285.57 
a = b = 
179.14, c = 
286.12 
a = b = 
179.99, c = 
287.98 
Resolution (Å) 
50-4.10 
(4.25-4.10) 
50-3.88 
(4.03-3.88) 
50-4.35 
(4.51-4.35) 
Total reflections 224,272 346,057 258,908 
Unique reflections 14,211 17,119 15,666 
Redundancy 2.5 (2.5) 3.2 (3.1) 3.3 (3.4) 
Completeness (%) 96.6 (98.7) 99.5 (98.8) 99.7 (99.9) 
Rsym(%) 8.9 (42.4) 9.0 (42.6) 9.2 (39.6) 
Average I/(I) 11.1 (1.8) 10.5 (2.1) 14.9 (2.0) 
Phasing     
Figure of merit 
(acentric/centric) 0.50/0.43 
  
Refinement  CusA-Cu(I) CusA-Ag(I) 
Resolution (Å)  50-3.88 50-4.35 
Rwork (%)  26.1 27.1 
Rfree (%)  29.6 31.2 
Protein residues built  1,015 1,014 
Protein atoms   7,802 7,782 
rms deviation from ideal    
      Bond lengths (Å)  0.005 0.006 
      Bond angles (°)  0.995 1.252 
Ramachandran      
 most favored   85.1 84.5 
 additional allowed   12.1 12.3 
 generously allowed  1.5 1.8 
 disallowed   1.2 1.4 
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Table S3. MICs of copper for different CusA mutants expressed in E. coli 
BL21(DE3)∆cueO∆cusA 
Gene in 
BL21(DE3)∆cueO∆cusA  
MIC (mM) of 
CuSO4 
Empty vector 0.50 
cusA (wild-type) 2.25 
cusA (M573I) 0.50 
cusA (M623I) 0.50 
cusA (M672I) 0.50 
cusA (M391I) 1.25 
cusA (M410I) 1.75 
cusA (M486I) 1.75 
cusA (M755I) 1.75 
cusA (M738I) 2.25 
cusA (M792I) 2.25 
cusA (D405A) 0.50 
cusA (E939A) 0.50 
cusA (K984A) 0.50 
cusA (E412A) 1.00
a 
cusA (S453A) 1.00
a 
cusA (C353A) 2.25
b 
cusA (C375A) 2.25
b 
 
a
Resdiues E412 and S453, located in the vicinity of the triad formed by D405, E939 and 
K984, may also involve in the proton-relay network. 
b
The CusA pump contains only two cysteine residues, C353 and C375, which may not 
involve in copper resistance.  
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Table S4. MICs of silver for different CusA mutants expressed in E. coli 
BL21(DE3)∆cueO∆cusA 
Gene in 
BL21(DE3)∆cueO∆cusA  
MIC (M) of 
AgNO3 
Empty vector 10.0 
cusA (wild-type) 30.0 
cusA (M573I) 12.5 
cusA (M623I) 12.5 
cusA (M672I) 12.5 
cusA (M391I) 10.0 
cusA (M410I) 17.5 
cusA (M486I) 17.5 
cusA (M755I) 12.5 
cusA (M738I) 30.0 
cusA (M792I) 30.0 
cusA (D405A) 12.5 
cusA (E939A) 12.5 
cusA (K984A) 12.5 
cusA (E412A) 12.5
a 
cusA (S453A) 15.0
a 
 
a
Resdiues E412 and S453, located in the vicinity of the triad formed by D405, E939 and 
K984, may also involve in the proton-relay network. 
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Supplemental Figures and Captions 
 
 
 
a 
b 
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Fig. S1. Stereo view of the experimental electron density map at a resolution of 3.8 Å.  (a) 
The electron density map contoured at 1.2  is in blue.  Each subunit of CusA consists of 34 
methionines.  33 selenium sites are found with a single SeMet crystal.  The anomalous maps 
of the selenium sites contoured at 4  are in green. The C traces of CusA are in red.  (b) 
Anomalous maps of the 33 selenium sites (contoured at 4 ).  The selenium sites 
corresponding to the 11 methionines forming the methionine-residue relay network are in 
green.  The rest of the 22 selenium sites are in purple.  The C traces of CusA are in red.  (c) 
Representative section of the electron density in the second domain of CusA.  The electron 
density (colored blue) is contoured at the 1.2  level and superimposed with the final refined 
model (yellow, carbon; red, oxygen; blue, nitrogen). 
  
c 
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Fig. S2. Sequence and topology of CusA and AcrB.  Alignment of the amino acid sequences 
of CusA and AcrB were done using CLUSTAL W.  *, identical residues; :, >60% 
homologous residues.  Secondary structural elements are indicated: TM, transmembrane 
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helix; N and N, helix and strand, respectively, in the N-terminal half; C and C, helix 
and strand, respectively, in the C-terminal half.  The CusC or TolC docking domain is 
divided into two sub-domains, DN and DC; whereas the pore domain is divided into four 
sub-domains, PN1, PN2, PC1 and PC2.  The sequence and topology of CusA are shown at 
the top, and those for the AcrB pump are shown at the bottom.   
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Fig. S3.  Experimental electron density of the periplasmic domain of CusA.  (a)  The electron 
density map of apo-CusA (3.8 Å-resolution) contoured at 1.2  is in blue.  The C traces of 
the periplasmic domain of apo-CusA are in red.  (b) The electron density map of CusA-Cu(I) 
(4.1 Å-resolution) contoured at 1.2  is in purple.  The C traces of the periplasmic domain 
of CusA-Cu(I) are in green.  The bound copper is shown as a brown sphere. 
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Fig. S4. Ion pairs in the transmembrane domain viewed from the cytoplasmic side.  
Residues D405 of TM4, E939 of TM10 and K984 of TM11 that form ion pairs, which may 
play an important role in proton translocation, are in yellow sticks.  The six methionines, 
M391, M403, M410, M486, M501 and M1009, are shown as pink sticks. 
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Fig. S5. Docking of CusB to CusA.  (a) Side view of the docked complex of CusBA.  The 
three CusB protomers are shown in green ribbons.  The trimeric CusA is in gray surfaces.  
Sub-domains PN2 and PC1 of CusA are in red and blue, respectively.  Specific interaction is 
found to occur between Domain 2 of CusB and the groove formed between DN and DC sub-
domains of CusA to further stabilize the complex.  (b) Top view of the docked complex of 
CusBA. 
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Fig. S6.  Stereo view of the methionine-residue relay network.  (a)  The transmembrane 
domain of a subunit of CusA viewed from the cytoplasmic side.  The six methionines that 
form three pairs in the transmembrane region are in green sticks.  (b) The periplasmic domain 
of a subunit of CusA viewed from the periplasmic side.  The five methionines that form a 
triad and a pair in the periplasmic domain are in green sticks. 
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Fig. S7. Alignment of amino acid sequences of the HME-RND-type Cu(I) and/or Ag(I) 
efflux pumps using CLUSTAL W.  *, identical residues; :, >60% homologous residues.  The 
alignment suggests that the methionine residues forming the relay network are conserved 
among these 30 different pumps.  Six of these methionines located at the transmembrane 
region are highlighted with gray bars. 
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Fig. S8.  Channel in the CusA pump.  (a) The channel formed by the front protomer of apo-
CusA (red) leading through the transmembrane and periplasmic domains is in gray color.  
The 11 methionines forming the relay network are in spheres (green, carbon; red, oxygen; 
blue, nitrogen; orange, sulfur).  The C atoms of the methionine pair, located at the top of the 
funnel, which does not involve in creating the channel are colored cyan.  Two other CusA 
protomers behind the front protomer are shown as blue wires.   (b) The channel formed by 
the front protomer of Cu(I) bound-CusA (green) leading through the transmembrane and 
periplasmic domains is in gray color.  The 11 methionines forming the relay network are in 
spheres (pink, carbon; red, oxygen; blue, nitrogen; orange, sulfur).  The C atoms of the 
methionine pair, located at the top of the funnel, which does not involve in creating the 
channel are colored cyan.  Two other CusA protomers behind the front protomer are shown 
as blue wires.  The funnel formed by sub-domains DN and DC is indicated with a dotted 
curve.  For clarity, the channels formed by the other two protomers at the back are omitted.  
The calculations were done using the program CAVER 
(http://loschmidt.chemi.muni.cz/caver). 
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Fig. S9.  A cartoon of a proteoliposome containing the CusA trimers.  The CusA trimers are 
in green.  The intravesicular space is loaded with the fluorescence indicator PGSK (blue star).  
Ag
+
 (red sphere) is then added into the extravesicular medium for metal transport. 
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Fig. S10.  Stopped-flow transport assay of reconstituted wild-type CusA with extravesicular 
Ag
+
 ion at different intravesicular and extravesicular pHs.  The stopped-flow traces are the 
cumulative average of four successive recordings (intravesicular pH = 6.6 and extravesicular 
pH = 7.0, black curve; intravesicular pH = extravesicular pH = 6.6, blue curve; intravesicular 
pH = extravesicular pH = 7.0, green curve; intravesicular pH = 7.0 and extravesicular pH = 
6.6, pink curve; control liposome, red curve). 
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Fig. S11.  The neighbor dependent opening closing motions. We show the effects of the 
strong internal motions on the CusA trimer.  In the center is a diagram of the periplasmic 
domain looking downward, towards the inner membrane.  We build an elastic network model 
using the formalism of Atilgan et al.
34
 to predict the natural motions of CusA.  On each of 
three sides we show the effect of two of the structure‟s natural motions.  These motions 
describe coupled opening and closing of adjacent periplasmic metal entry sites.  Black 
wedges are shown in open and closed form, indicating the approximate angle between the 
118 
 
edges of PC1 and PC2 in each motion.  From these the alternating open/close motion is 
evident. 
 
Fig. S12.  The swinging motion of PC2 coupled to TM8, as computed with the same elastic 
network model used for Fig. S11.  This motion is similar to the difference between the apo 
and bound crystal forms displayed in Fig. 2.  An arrow indicates the motion of swinging from 
the red conformation to the green.  For clarity PC2 and TM8 are shown in thicker lines than 
the remainder of the monomer. 
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Fig. 13.  Expression level of the CusA pumps.  An immunoblot against CusA of crude 
extracts from 50 g dry cells of strain BL21(DE3)∆cueO∆cusA expressing the CusA pumps 
(M755I, lane 1; M391I, lane 2; M410I, lane 3; M486I, lane 4; wild-type, lane 5; marker, lane 
6; M573I, lane 7; M623I, lane 8; M672I, lane 9) is shown.  
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CHAPTER 4.  General Conclusions and Future Directions 
Multidrug resistance of common pathogens is one of the most serious issues 
regarding human health.  To ensure their survival, bacteria have developed a mechanism that 
involves the expression of multidrug efflux transporters to subvert antibiotics and other toxic 
compounds.  In this dissertation, several efflux pumps belonging to different transporter 
families, such as MATE and RND, were functionally and structurally characterized.  
We have cloned, expressed and purified the N. gonorrhoeae NorM MATE-type 
transporter.  The functions of NorM and its homologous protein E. coli YdhE were examined 
using drug susceptibility and transport assays.  Both NorM and YdhE confer resistance to 
various antimicrobial agents in a similar but slightly different manner.  Direct measurements 
of drug efflux in living cells indicated that NorM behaves as a Na
+
/drug antiporter, which is 
consistent with the previous hypothesis that MATE transporters utilize Na
+ 
as the coupling 
cation.  Recently, a few efflux pumps, identified as MATE transporters, have been identified 
as H
+
/substrate antiporters.  These antiporters include PmpM of P. aeruginosa (1), AbeM of 
A. baumannii (2), and hMATE1 from human chromosome 17 (3).  The selection of cations 
for energy coupling is definitely not by random.  Thus, the question of how a bacterium 
selectively chooses a particular cation for better energy coupling remains to be elucidated.  
To this point, it is expected that the extracellular environment might somehow account for it 
(4).  The functional information of more MATE transporters is needed to uncover this energy 
coupling mechanism.  
The work of NorM of V. parahaemolyticus suggested that the three conserved anionic 
residues (Asp32, Glu251 and Asp367) in the predicted transmembrane regions are important 
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for the function of the pump (5).  Our preliminary results (not shown) from drug 
susceptibility assay also indicated that the corresponding mutants in N. gonorrhoeae NorM 
(Asp41, Glu261 and Asp377) are defective in drug resistance.  It is unclear how these 
charged residues involve in the operation of the active pumps.  Systematic and rational 
mutations should be made to elucidate the molecular mechanism that NorM utilizes to expel 
toxic compounds out of the cell.  The crystal structure of NorM appears to be essential to 
address this fundamental question.  Until now, the structural information of the MATE 
family transporters has not yet been available.  Preliminary crystallization study of NorM in 
our laboratory has shown that the best crystal diffracted to a resolution of 3.8 Å, thus 
providing us with a strong foundation in optimizing the crystallization conditions and 
hopefully having the crystal structure determined (6). 
In this dissertation, we have determined the crystal structure of CusA, which serves as 
the first three-dimensional structural model of the HME-RND efflux pumps.  A major 
conformational change was revealed by comparing the crystal structures with and without 
Cu(I) and Ag(I).  The metal binding site, located at the periplasmic domain, is formed by 
three methionines (M573, M623 and M672).  Based on the crystal structures, we proposed 
that the metal ion is exported through a methionine-residue relay network which involves 
five methionine pairs/clusters in the pump.  We also performed metal transport assay using 
proteoliposomes.  The results suggest that these methionine pairs/clusters are essential for the 
active efflux of silver ions.  In addition, we have also identified three charged residues that 
form the proton relay network of the pump.  Sequence alignment among different RND 
efflux pumps shows these charged residues, located at the transmembrane domain, are 
conserved among the HME-RND efflux pumps. 
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It has been generally accepted that the RND-type transporters operate through an 
alternating-access mechanism that involves the asymmetric conformation of the trimeric 
pump (7, 8).  Thus, CusA may go through a cyclic conformational change, from the “access”, 
through the “binding” and finally to the “extrusion” conformers of the trimeric pump to 
export metal ions.  With the development of the single molecule technique, it is possible to 
capture the functional dynamics of CusA during metal export. 
The study of AcrB tripartite system suggested that AcrB is likely to capture its 
substrates from the periplasm (9).  It is not known if AcrB could pick up drug molecules 
from the cytoplasm.  Our proposed metal export pathway suggests that CusA is capable of 
accepting the metal ions through both the cytoplasm and periplasm.  This may imply that the 
RND pumps may be able to detoxify the interior of the cell by picking up toxic compounds 
both from the cytoplasmic and periplasmic spaces.  The fact that substrate can be directly 
transported from the cytoplasm is also supported by the works of other RND transporters.  
For example, the C. metallidurans CzcA HME-RND transporter has been found to export 
Zn
2+
 ions through the cytoplasm (10).  Further, these RND transporters are also found in 
Gram-positive bacteria (YerP, ActII3) (11, 12), mycobacteria (MmpL7) (13, 14), and human 
cells (NPC1) (15, 16), in which both of these cells possess only one single layer of cell 
membrane. 
To understand how the RND pumps operate to mediate drug and toxic chemical 
resistance, the crystal structure of the tripartite efflux complex is essential.  Currently, our 
laboratory is in the process of crystallizing the CusBA and CusCBA complexes.  It is 
expected that the complex structures will allow us to uncover the mechanisms by which the 
RND transporters employ to export toxic substances.  
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